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ABSTRACT 
 
MS is a chronic demyelinating disease affecting OLs, responsible for 
axon myelination in the CNS. Remyelination, in MS lesions, is dependent on 
the recruitment and differentiation of OPCs. 
During inflammation high levels of ROS can be achieved within MS 
lesions changing the local environment where OPCs differentiation occurs. 
Moreover, in chronic MS lesions OPCs accumulate with loss of mature OLs, 
suggesting the existence of a differentiation block of OPCs. 
We investigated the effects of low and high ROS levels, on signaling 
pathways involved and the role of the main source of ROS, NADPH-oxidase 
(NOX) enzymes, in OPCs differentiation. 
We also tested the hypothesis of the presence of autoantibodies 
impairing OPCs differentiation in CSF or in serum of MS patients. 
Our results demonstrated that OPCs, exposed to mild oxidative-stress, 
increase expression of OLs differentiation markers; thus ROS mediate the 
signals leading to OPCs differentiation. 
Fine tuning of the type and the levels of ROS generated by NOX–PKC 
signals may have profound effects on OPCs differentiation. Thus, large 
amounts of ROS induce death of OPCs. 
This finding is relevant for the pathogenesis of MS lesions: whereas 
low ROS in limited inflammation may represent a positive re-myelination 
stimulus, excess of ROS produced by extensive inflammation may reduce the 
pool the OLs precursors and worsen MS lesions. 
In addiction, our data indicate that CSF and autoantibodies present in 
the IgG fraction from serum of MS patients inhibit OLs differentiation thus 
impairing myelination in CNS. 
 
 2 
CHAPTER I 
INTRODUCTION 
 
1.1. Multiple Sclerosis 
Multiple sclerosis (MS) is characterized by a chronic demyelinating 
inflammation, damaging the central nervous system (CNS) (1, 2). MS is the 
most common cause of disability in young adults. As in other chronic 
inflammatory diseases, the manifestations of MS change from a benign to a 
rapidly progressive and disabling form. Some indirect data suggest an 
autoimmune etiology for MS, perhaps triggered by a viral infection, in 
genetically susceptible individuals (3). Despite the number of studies on the 
disease and a multidisciplinary approach to the problem, the pathogenesis of 
MS is still obscure and the etiology is unknown. 
 
1.1.1. Histopathology 
The term MS derives from multiple sclerotic areas visible in 
macroscopic examination of the brain. These lesions, called plaques, are 
easily distinguishable from the surrounding white matter. The plaques vary in 
size from 1-2 mm to several centimetres. The acute lesion of MS, which is 
rarely found in a post mortem examination, is characterized by infiltration of 
mononuclear cells (mainly T lymphocytes and macrophages) and loss of 
myelin (demyelination). Myelin (Figure 1), formed by glial cells named 
oligodendrocytes (OLs), constitutes the sheath that insulates nerve cell 
extensions, allowing the rapid and integral transmission of nerve impulses. 
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Figure 1. Cross section of white-matter lesions targeting the myelin sheath and 
oligodendrocytes. 
Panel A - Light microscopy reveals myelin sheaths (dark blue rings) around axons in a 
cross section of myelinated white matter (toluidine blue). Two darkerstaining OLs, the 
cells that make and maintain myelin, lie to the right of center (arrow). 
Panel B - An electron micrograph reveals the myelin sheath in cross section to be a 
spirally wrapped membrane beginning in the lower left as an outer (oligodendroglial) 
“tongue” of cytoplasm and spiraling counterclockwise to terminate at an inner tongue 
inside the myelin sheath to the right of the axon. Microtubules and neurofilaments can be 
seen cut in cross section within the axoplasm. 
(Elliot M. Frohman et al. -Multiple Sclerosis-The plaque and its pathogenesis-N Engl J 
Med 2006). 
 
 
 
 
With the progression of the disease the destruction of myelin sheaths 
causes blocking or slowing of nerve impulses. The inflammatory infiltrates 
appear to mediate the loss of the myelin sheath surrounding the axon cylinder. 
With the progression of the lesion, a large number of macrophages and 
microglial cells (phagocytes specialize in the CNS that derive from bone 
marrow) digests myelin fragments and astrocytes proliferate (gliosis). In 
chronic lesions are present a complete or nearly complete demyelination and 
dense gliosis (Figure 2) (4). 
A B 
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Figure 2. Chronic lesions of multiple sclerosis in Humans. 
Panel A - An electron micrograph of a chronic active lesion shows a myelinated fiber 
undergoing demyelination. The arrow shows myelin droplets on the macrophage surface 
being internalized by the cell. The fiber is invested by a microglial cell, which is engaged 
in the phagocytosis of myelin droplets as they are divested from the myelin sheath. The 
end product of this process is shown in Panel B (toluidine blue stain). Panel B - An area 
from a chronic silent gliotic lesion is made up of astroglial scar tissue, in which intact 
demyelinated axons (light profiles) are embedded; mitochrondria can be seen within the 
axons; the smaller nuclei belong to microglial cells, but no oligodendrocytes are present. 
Panel C - An electron micrograph with a field similar to that in Panel B shows large-
diameter demyelinated axons (A) within the glial scar; an astroglial-cell body is at the 
upper right. Panel D - (toluidine blue stain) A biopsy specimen from a patient with 
secondary progressive multiple sclerosis shows an area of remyelination (shadow plaque) 
in which the myelin sheaths of many axons are disproportionately thin and OLs are 
overabundant. These cells are probably oligodendroglial precursor cells recently recruited 
into the lesion. Panel E - An electron micrograph shows remyelination; the myelin sheaths 
are thin in comparison to the diameters of the axons, and two OLs are evident (OL).Panel 
F - (Luxol fast blue and periodic acid–Schiff) There is an abrupt transition at the edge of 
the chronic MS lesion. The myelin internodes (blue) terminate sharply at the demyelinated 
plaque. OLs are present (arrows) up to the edge of the lesion, but not within the lesion. Rod 
cells (microglia) are lined up along the boundary. A denotes axon, and As astrocyte. 
(Elliot M. Frohman et al. –Multiple Sclerosis-The plaque and its pathogenesis-N Engl J 
Med 2006). 
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1.1.2. Epidemiology  
MS is the most common neurological disease in young adult and, as 
shown by the descriptive studies, the geographical distribution of the disease 
is non homogeneous (5). It is frequent in the countries in central and northern 
part of Europe and in those non-European regions of northern European 
ancestry. MS is typically a disease of temperate climates; in both hemispheres 
its prevalence decreases with decreasing latitude (Figure 3). 
 
 
Figure 3. Prevalence of MS related to latitude. 
MS is typically a disease of temperate climates; in both hemispheres its prevalence 
decreases with decreasing latitude. 
 
The comparison between the populations of North America and Europe 
indicates similar rates of prevalence and similar north-south gradient. Some 
areas of the world represent real focus of the disease (in Italy, Sardinia) (6, 7), 
suggesting that in MS there are environmental factors. Italy is one of the 
countries with a higher risk of developing the disease (Figure 4). The number 
of affected subjects in Italy is approximatively 50.000 and more than 1.1 
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million worldwide. In Caucasians, the average rates of total prevalence vary 
between 30 and 180 cases/100.000 inhabitants (5) and the incidence is 10-20 
new cases/100.000 inhabitants per year. It is most frequently diagnosed 
between 20 and 40 years, rarely affects children and the elderly. MS is about 
twice as common in women than in men (8, 9). 
 
 
Figure 4. Prevalence of MS per 100.000 inhabitants. 
Globally, the median estimated prevalence of MS is 30 per 100.000 (with a range of 5–80). 
Regionally, the median estimated prevalence of MS is greatest in Europe (80 per 100.000), 
followed by the Eastern Mediterranean (14.9), the Americas (8.3), the Western Pacific (5), 
South-East Asia (2.8) and Africa (0.3). (The Atlas of MS 2008). 
 
1.1.3. Pathogenesis 
MS can be considered the result of complex multifactorial interactions 
between genetic and environmental factors. Several studies suggest that MS is 
an immune-mediated disease related to T lymphocytes action and induced by 
external and unknown agents, such as viruses and bacteria, in selected 
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subjects. Most researchers seem to agree that the demyelination process 
includes at least three main factors:  
 a particular immunogenetic pattern; 
 an immunopathologic mechanism; 
 environmental factors. 
 
IMMUNOGENETIC FACTORS  
The evidence related to the influence of genetic factors in the 
pathogenesis of MS derives from studies of families and twins (10-13). These 
studies have shown that the disease risk is higher in the biologically related 
family members with MS patients, compared to the general population (14). 
These findings also suggest a common sharing of exposure to environmental 
risk factors during critical periods of risk (childhood and adolescence). 
However, Ebers et al. (1995) have shown that the disease risk in non-
consanguineous first degree relatives, adopted individuals, living with MS 
patients is similar to the expected value from the general population. In 
Caucasian patients with MS, population genetic studies have demonstrated an 
association with major histocompatibility complex (MHC) class II alleles 
(DRB1*1501, DRB5*0101 and DQB1*0602) (15). These alleles, in humans, 
are contained in HLA-DR2 haplotype, that is the most frequently associated 
with the disease in Caucasians. The genotypic and phenotypic analysis shows 
that the susceptibility is probably oligogenic or multigenic type and mediated 
by a set of genes that interact in a epistatic way (16, 17). In this interaction a 
specific genetic locus may influence the phenotypic expression of the another 
locus (18). 
 
IMMUNOPATHOLOGICAL MECHANISM 
MS seems to be a disease with autoimmune pathogenesis and it is 
mediated, at least in part, by T lymphocytes. In the autoimmune diseases there 
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is an alteration of the immune system, autoreactive to endogenous self-
peptides. In MS the myelin is not more recognized as self-peptide (19-21). 
Normally, in our immune system the T cells play a key role in defence against 
foreign pathogens, such as viruses, bacteria and allergens. In MS, the T cells 
attack the myelin of the CNS (22-25). 
Previous studies have showed that peptide sequences of very common 
viral agents, such as Epstein Barr virus (EBV) (26, 27), influenza virus type A 
(28), human papilloma virus (HPV) (29) and human herpes virus type 6 
(HHV-6) (30, 31) are very similar to Myelin Basic Protein (MBP). Another 
virus, John Cunningham Virus (JCV), is a type of human polyomavirus 
(formerly known as papovavirus) and is genetically similar to BK virus and 
SV40. It was discovered in 1971 and named with the two initials of a patient 
(JC) with progressive multifocal leukoencephalopathy. This virus is able to 
infect OLs and has been shown to be reactivated in MS patients treated with 
interferon (32). The inflammatory reaction is associated with up-regulation of 
several Th1 cytokines, including interleukin 2 (IL-2), interferon-gamma (IFN-
γ) and tumor necrosis factor-alpha (TNF-α) that were found in the 
cerebrospinal fluid (CSF) from patients with the disease (33, 34). The 
endothelial cells of the brain and spinal cord, triggered by demyelinating 
lesions, express adhesion molecules, fibronectin, the receptor for urokinase 
plasminogen activator (uPAR), the MHC class II molecules, chemokines and 
stress proteins (35). Magnetic resonance imaging (MRI) studies in the early 
stages of disease suggest that most of the lesions is preceded by focal 
destruction of blood brain barrier (BBB); therefore, this condition would 
facilitate entry of autoreactive T cells and antibodies inside the CNS (36). 
Recently, in experimental models of encephalomyelitis (EAE) it has been 
shown that the breaking of the BBB is initiated by memory T cells expressing 
CCR-6, the receptor for the chemoattractant molecule CCL-20. These cells 
escape from choroid plexus vessels, penetrate into stroma and cross the 
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epithelial-choroid plexus barrier (37). The histopathological effect of this 
inflammatory mechanisms is the demyelination, that is the formation of a 
plaque, indicating damage to the myelin sheath. The neuron, therefore, devoid 
of the myelin sheath, loses the capability to transmit nerve signals leading to 
the appearance of a sign or a symptom. Neuropathological studies of MS 
lesions have clearly demonstrated a remyelination process, but this process is 
incomplete in chronic lesions and usually limited to the edges of 
demyelinating plaques. 
ENVIRONMENTAL FACTORS 
Several epidemiological data suggest the intervention of environmental 
factors in the genesis of MS. Environmental factors proposed as possible risk 
factors of MS are: 
 specific or common bacteria or virus, 
 heavy metal poisoning, 
 industrial pollution, 
 hygiene, 
 diet, 
 climate. 
Individuals emigrated from high risk areas of disease in low risk areas, 
such as South Africa (38) or Hawaii (39), maintained the risk level of their 
country of origin. However, this trend was valid only for individuals 
emigrated after the age of 15 years (38). The individuals emigrated during 
childhood or before adolescence acquired the same risk of host countries. 
These data suggest that environmental factors influence the individual just 
before puberty (about 15 years) (40). 
The prevalence and the incidence of MS show large differences within 
high risk areas with stable and ethnically homogeneous populations (5). 
Therefore, the MS could be a disease with a non homogeneous distribution 
both in space and time. Thus, it is possible that the etiologic agent responsible 
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for the disease spreads from area to area, from a population to other and it 
must be able to change its concentration over time. These qualities seem 
typical of an infectious agents. One of the most important epidemiological 
studies on MS describes the dramatic increase in the incidence of the disease 
in the Faroe Islands (North Atlantic, west of Norway), after the military 
occupation by 1500-2000 soldiers of the British troops between 1941 and 
1944 (41). This event shows that the environmental factor is not only 
endemic, but may be transported from one area to another. From these 
observations and from the association between the upper airways viral 
infections and relapsing MS and T cell cross-reactivity between proteins of 
the myelin sheath and viral antigens, the viruses have attracted the attention of 
researchers (42, 43). The viruses mostly investigated are: HHV-6, for its 
neurotrophism (30, 31), Epstein-Barr virus according to an action 
characterized by “molecular mimicry” (26, 27) and LM7 retrovirus, know as 
“multiple sclerosis associated retrovirus” (MSRV) (44, 45). Nevertheless, no 
viral agent has been conclusively linked to MS. It is likely that various 
infectious agents, also non-specific, induce, under certain circumstances, an 
immune response against self-antigens (46). Recent studies have shown that 
heavy metal poisoning (47), industrial pollution and hygiene can contribute to 
onset of the disease. Finally, an environmental factor is currently, attracting 
great interest: nutrition (48). The different dietary habits, in fact, seem to 
provide satisfactory explanations for the non homogeneous distribution of MS 
in different geographical areas. 
 
1.1.4. Clinical manifestations 
The symptoms of MS are extremely various and not specific to the 
disease. In fact, many diseases such as cancer, stroke, systemic lupus 
erythematosus (SLE), vasculitis and other less severe diseases have, at least in 
part, common signs and/or symptoms with MS (49). The appearance of the 
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disease can be sudden or slow. The symptoms at onset can be severe or so 
slight not to require medical attention even after months from the onset. The 
nature of the symptoms depends on the lesion location (or plaque) in CNS. 
The most common symptoms at onset include weakness in one or more limbs, 
blurred vision, due to optic neuritis, abnormal sensitivity, diplopia and ataxia. 
In order to standardize the terminology to describe the clinical course and the 
subtypes of the disease, it has been created a task force of 215 experts, 
members of the international MS scientific community (50), which identified 
four types of disease: 
RELAPSING-REMITTING MS: is the most common form of MS in the 
people under 40 years and it represents the 45-50% of people with MS. The 
subjects are struck by acute attacks, also named exacerbations, followed by 
periods of remission, during which the patients fully or partially recover. This 
clinical variant evolves in 80% of cases in the secondary progressive form. 
SECONDARY PROGRESSIVE MS: characterized by a continuous disease 
progression after a period of time attributable to the relapsing-remitting type, 
with or without relapses or remissions. The recovery after exacerbations is 
incomplete, resulting in a progressive deterioration of physical conditions 
over time. It affects approximately 25-30% of patients with MS. 
PRIMARY PROGRESSIVE MS: gradual progression of the disease from its 
onset. The signs and symptoms accumulate gradually over time without the 
appearance of a real attack and without remissions, but rarely causing 
permanent disability, because the course is very slow. This form is more 
common in subjects presenting their first symptoms after age 40 
(approximately 10-15% of patients with MS). 
PROGRESSIVE RELAPSING MS: the patients with a primary progressive 
MS may have relapses. The intervals between relapses are characterized by a 
continuous progression of the disease, unlike relapsing-remitting MS. It 
affects 2-5% of subjects with MS. 
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A BENIGN DISEASE indicates the lack of detection of neurological deficit 
15 years from onset with complete remission (10% of patients). On the 
contrary, MALIGNANT DISEASE is characterized by a rapid and progressive 
course that causes multiple neurological deficits or death in a short period of 
time (5% of patients). 
1.1.5. Diagnosis 
No definitive diagnostic tests for MS is currently available. Therefore, 
to reach a definitive diganosis it is necessary to use different tools derived 
from clinical analysis (51), laboratory (52) and instrumental tests (53, 54). 
1) CLINICAL DIAGNOSIS analyzes: 
 Patient medical history; 
 Evidence of altered sensibility, impaired strength and vision 
disturbances; 
 Symptoms/signs attributable to white matter lesions are not 
justified by other diseases; 
 Spatial dissemination of lesions with clinical signs referable to 2 
or more lesions; 
 Symptoms/signs attributable to the temporal dissemination of the 
lesions: two or more relapses; 
2) LABORATORY DIAGNOSIS is based on CSF investigations 
(inflammatory and autoimmune disorders), assaying the intrathecal 
synthesis of Immunoglobulins G (IgG) and the presence of 
oligoclonal Ig bands. 
3) INSTRUMENTAL DIAGNOSIS: 
 Magnetic Resonance Imaging (MRI) detects pathological foci in 
the brain stem, cerebellum and spinal cord and the presence of 
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lesions in the corpus callosum and the ventricles. In addition, 
through the use of contrast medium it is possible highlight local 
impairments in BBB preceding the signs of exacerbation and 
possible injury to the optic nerve. 
 Computerized Axial Tomography (CAT) shows less dense areas 
around the ventricles corresponding to the plaques where the 
myelin is lost. 
 Testing of Evoked Potentials (EP) measures the transmission 
time of sensory messages that travel through the nerves. 
In MS the diagnostic procedure is rather long and tortuous and at 
present the only diagnostic support provided by the laboratory is based on 
analysis of intrathecal IgG synthesis and research of oligoclonal Ig bands. 
The CSF constitutes the extra-cellular component of the CNS and it is 
separated from the systemic circulation only through the BBB. The IgG 
dosage in CSF and serum appears of same clinical interest. Numerous 
formulas have been used to distinguish the IgG synthesized locally by those in 
serum, which may enter the CNS passively through an altered BBB. An 
useful formula expresses the relationship between IgG and CSF albumin and 
IgG and serum albumin ("index LCS-IgG”). This quantitative analysis is 
simple and rapid, but not specific. Therefore, a more specific test is based on 
the research of oligoclonal Ig bands. 
The presence of oligoclonal Ig bands in the CSF is carried out through 
the lumbar puncture (colloquially know as a spinal tap). The spinal needle 
inserted between the lumbar vertebrae L3/L4 or L4/L5. The γ-globulin region 
in CSF appears perfectly homogeneous in the serum. The intrathecal IgG 
synthesis in CSF is represented by the appearance of small discrete bands in 
the γ -globulin region that becomes non homogeneous. Oligoclonal bands are 
thin strips composed of IgG antibodies that migrate on an appropriate agarose 
or polyacrylamide gel, according to their isoelectric point and constant pH. 
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The test provides an initial separation of the proteins by their isoelectric point, 
they are transfered to a nitrocellulose membrane and then they are 
immunodetected with anti-IgG conjugated to peroxidase. The presence of one 
band (a monoclonal band) is not considered significant. The presence of two 
or more bands appears specific. This test is laborious, requires a fair 
experience of the operator and gives exclusively qualitative results (mostly 
based on a subjective estimate). Regarding the sensitivity and the accuracy of 
the test to identify MS patients, the presence of oligoclonal IgG bands has a 
75% sensitivity and 85% specificity. This means that 1/4 of MS patients are 
negative (false negatives) and 1/6 of healthy patients are positive in this test 
(false positives). Another problem of the analysis of oligoclonal bands is the 
low reproducibility. This is due to a subjective estimate of the final result, 
misinterpretation of experimental artefacts, lack of a solid technical 
experience (55). 
1.2. Oligodendrocytes 
Glial cells, commonly called neuroglia or simply glia, are non-neuronal 
cells that maintain homeostasis, form myelin, and provide support and 
protection for the brain's neurons. It is divided in microglia and macroglia 
(composed by astrocytes, OLs, ependymal cells and radial glia in CNS). 
The most abundant type of macroglia cell, astrocytes (also called 
astroglia) have numerous projections that anchor neurons to their blood 
supply. They regulate the external chemical environment of neurons by 
removing excess ions, notably potassium, and recycling neurotransmitters 
released during synaptic transmission. 
Ependymal cells, also named ependymocytes, line the cavities of the 
CNS and make up the walls of the ventricles. These cells create and secrete 
CSF and beat their cilia to help circulate CSF. 
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OLs are cells that coat axons in the CNS with their cell membrane 
forming a specialized membrane differentiation called myelin, producing the 
so-called myelin sheath. The myelin sheath provides insulation to the axon 
that allows electrical signals to propagate more efficiently (Figure 5). 
 
 
Figure 5. Glia cells. 
A oligodendrocyte simultaneously wrapping multiple axons with a myelin sheath. Also 
shown are nodes of Ranvier, which are small unmyelinated axonal regions. (Silverthorn 
Dee U.). 
 
Oligodendroglia derive during development from oligodendrocyte 
precursor cells (OPCs), which can be identified by their expression of a 
number of antigens, including the ganglioside GD3 (56, 57), the NG2 
chondroitin sulfate proteoglycan, and the platelet-derived growth factor-alpha 
receptor subunit (PDGF-αR). In the rat forebrain, the majority of 
oligodendroglial progenitors arise during late embryogenesis and early 
postnatal development from cells of the sub-ventricular zones (SVZ) of the 
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lateral ventricles. SVZ cells migrate away from germinal zones to populate 
both developing white and gray matter, where they differentiate and mature 
into myelin-forming oligodendroglia (57, 58). However, it is not clear 
whether all oligodendroglial progenitors undergo this sequence of events. It 
has been suggested that some undergo apoptosis and others fail to 
differentiate into mature oligodendroglia but persist as adult oligodendroglial 
progenitors (59). 
1.2.1. Function of Oligodendrocytes 
As part of the nervous system, OLs are closely related to nerve cells, 
and, like all other glial cells, OLs provide a supporting role for neurons. In 
addition, the nervous system of mammals depends crucially on myelin 
sheaths, which reduce ion leakage and decrease the capacitance of the cell 
membrane. Myelin also increases impulse speed, as saltatory propagation of 
action potentials occurs at the nodes of Ranvier in between Schwann cells (of 
the peripheral nervous systems -PNS) and OLs (of the CNS). OLs provide the 
same functionality as the insulation on a household electrical wire (with the 
rather large difference that, while household electrical wires are in a non-
conducting medium - air - the axons run in a solution of water and ions, which 
conducts electrical current well). Furthermore, impulse speed of myelinated 
axons increases linearly with the axon diameter, whereas the impulse speed of 
unmyelinated cells increases only with the square root of the diameter. In 
contrast, satellite OLs are functionally distinct from most OLs. They are not 
attached to neurons and, therefore, do not serve an insulating role. They 
remain opposed to neurons and regulate the extracellular fluid (60). 
 
1.2.2. Myelin 
The myelin sheath around most axons constitutes the most abundant 
membrane structure in the vertebrate nervous system. Its unique composition 
(richness in lipids and low water content allowing the electrical insulation of 
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axons) and its unique segmental structure responsible for the saltatory 
conduction of nerve impulses allow the myelin sheath to support the fast 
nerve conduction in the thin fibers in the vertebrate system. High-speed 
conduction, fidelity of transfer signaling on long distances, and space 
economy are the three major advantages conferred to the vertebrate nervous 
system by the myelin sheath, in contrast to the invertebrate nervous system 
where rapid conduction is accompanied by increased axonal calibers. 
Myelin proteins, which comprise 30% dry weight of myelin, are for 
most of the known ones, specific components of myelin and OLs. 
The major CNS myelin proteins, MBP and Proteolipidic Protein (PLP) 
(and isoform DM-20), are low-molecular-weight proteins and constitute 80% 
of the total proteins. Another group of myelin proteins, insoluble after 
solubilization of purified myelin in chloroform-methanol 2:1, have been 
designated as the Wolfgram proteins, since their existence was suspected 
already in 1966 by Wolfgram. These proteins comprise the 2’,3’-cyclic 
nucleotide-3’-phosphohydrolase (CNP) and other proteins (60). 
1.2.3. Myelination 
Myelination consists of the formation of a membrane with a fixed 
composition and specific lipid-protein interactions allowing membrane 
compaction and the formation of the dense and intraperiodic lines of myelin. 
Therefore, myelination also needs activation of numerous enzymes of lipid 
metabolism necessary for the synthesis of myelin lipids, of synthesis and 
transport of specific protein components of myelin or their mRNAs to the 
OLs processes. 
These are the sequential steps governing myelination: 
1. the migration of OLs to axons that are to be myelinated, and 
the fact that axons and not dendrites are recognized; 
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2. the adhesion of the OL process to the axon; 
3. the spiraling of the process around the axon, with a 
predetermined number of myelin sheaths and the recognition 
of the space not to be myelinated, i.e., the nodes of Ranvier 
(60). 
In the first step, the pre-oligodendroglial multiprocessed cells settle 
along the fiber tracts of the future white matter, maintaining the ability to 
divide. Indeed, mitoses are present in the interfascicular longitudinal glial 
rows (61). Second, these pre-OLs become immature OLs, characterized by 
the acquisition of specific markers and ready for myelination. 
 
1.2.4. Remyelination 
The OLs and the myelin sheath are the main targets of the pathological 
process in MS. The loss of OLs involves the demyelination, and thus a 
considerable loss of efficiency of axons to conduct impulses (1, 2). After the 
demyelination a spontaneous regenerative or healing process by which new 
myelin layers are formed around demyelinated axons, is taking place. This 
process is named remyelination, which allows axons to restore efficient 
conduction of nerve impulses. In the first stage of the disease, when the 
axonal degeneration is not significant, the demyelinating injury is 
compensated by remyelinization (62). 
The remyelination is mediated by a population of stem cells abundantly 
distributed in the adult CNS. These cells are the OPCs, and the inflammation 
is vital to stimulate, inside of the lesion, the production of factors that 
promote the recruitment of these precursors (63). Soon the demyelination area 
is filled by the OPCs that have the ability to proliferate and differentiate into 
mature OLs, producing new myelin sheath around the demyelinated axons 
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(64, 65). The continuous maturation of these cells ensures a continuous 
process of myelin formation. This correcting mechanism is not perfect and 
limited to the early stages of the disease. 
In MS it is not known whether the remyelination is slowed or blocked. 
The failed remyelination in MS has been associated with limited availability, 
migratory capability or myelination of the OPCs. Previous studies have 
shown that in chronic demyelinating lesions in MS patients there is a small 
number of pro-OLs and an increased number of OPCs, suggesting the 
presence of defective mechanism in the OPCs maturation (66, 67). 
 
 
1.2.5. Oligodendrocyte proliferation and differentiation 
The growth and the development of neuronal cells is controlled by a set 
of different factors: NGF, IGF II, laminin, fibronectin, collagen and adhesion 
molecules such as N-CAM and cadherins (68). Moreover, in the adult brain 
the turnover and the replacement of OLs, as well as the remyelination process, 
are phenomena that occur continuously. The brain contain endogenous OPCs 
with the ability to proliferate and differentiate into mature OLs, through the 
stages of Pro-OL and immature OL, producing new myelin sheath around the 
demyelinated axons (Figure 6) (69, 70). The oligodendrocyte precursors are 
present during the development of the nervous system, but some of them 
remain in the fully developed brain. They constitute the largest group of cells 
subjected to mitosis in the adult brain. 
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Figure 6. Immunophenotype and morphology of perinatal oligodendrocyte lineage 
cells in culture. 
The name of the cell type is listed along the top, with the most immature stage, the pre-O-
2A or pre-progenitor, at the left and the most differentiated stage, the mature 
oligodendrocyte, at the right (71). 
 
The generation of OPCs by neural stem cells is the result of interaction 
of local extrinsic induction factors (SHH, FGF2, PDGF, IGF1, neurotrophins) 
(72-74) with proteins of the intrinsic transcription machinery of CNS (75). 
The neurotrophins (NGF, BDNF, NT-3, NT-4/5) are small secreted 
proteins in the nervous system and are important in the differentiation, 
migration, proliferation and activation of cells of the CNS. In fact, BDNF and 
NT3 are required for survival and myelination (76). The first transcription 
factors in the differentiating of OPCs in spinal cord and forebrain (therefore 
used as markers for early OPCs) are Olig-1 and Olig-2, members of the basic 
helix-loop-helix (bHLH) family (75). Olig-2 leads to the generation of OPCs, 
while Olig1 seems involved in the survival and maturation of OPCs. 
A second group of transcription factors crucially involved in OPC 
differentiation includes members of the Sox family. In particular, Sox8, Sox 9 
and Sox10 are expressed in OPCs directly after induction of OL lineage and, 
therefore, are also frequently used as markers for early OPCs. Sox5 and Sox6 
are involved in the progression of OPCs differentiation towards more mature 
stages (77, 78). In addition, three members of the homeodomain transcription 
factor family, Nkx2.2, Nkx6.1 and Nkx6.2 (74), along with two members of 
the Zinc-finger superfamily of trascription factors: Myt1 and YinYang1, seem 
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to play a role in the differentiation of the oligodendrocyte progenitors (79, 
80). 
1.2.6. Factors influencing oligodendrocyte maturation and survival 
Many growth factors have been found to be involved in the 
proliferation, differentiation, and maturation of the oligodendrocyte lineage. 
- PDGF. Platelet Derived Growth Factor (PDGF) is 
synthesized during development by both astrocytes and neurons. In 
vitro, PDGF, a survival factor for oligodendrocyte precursors, is a 
potent mitogen for OPCs, although it triggers only a limited number of 
cell divisions. PDGF is also a survival factor for oligodendrocyte 
progenitors, as recently demonstrated by the impaired OL development 
in the PDGF-α deficient mice. In these mice, there are profound 
reductions in the numbers of PDGFR-α progenitors and OLs in the 
spinal cord and cerebellum, but less severe reductions of both cell types 
in the medulla. Infusion of PDGF into the developing optic nerve in 
vivo greatly reduces apoptotic cell death (81). PDGF also stimulates 
motility of oligodendrocyte progenitors in vitro and is chemoattractive. 
- BASIC FGF. Basic Fibroblast Growth Factor (bFGF) (also 
called FGF 2) is also a mitogen for neonatal oligodendrocyte 
progenitors. It upregulates the expression of PDGFR-a and therefore 
increases the developmental period during which oligodendrocyte 
progenitors or pre-OLs are able to respond to PDGF (82). Pre-OLs can 
even revert to the oligodendrocyte progenitor stage when cultured with 
both PDGF and bFGF. This inhibition of oligodendrocyte 
differentiation can be overridden by the presence of astrocytes. bFGF is 
present in the developing nervous system in vivo. The levels of 
expression of mRNA for the high-affinity bFGF receptors-1, -2, and -3 
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are differentially regulated during lineage progression (83); this pattern 
of expression could provide a molecular basis for the varying response 
of cells to a common ligand that is seen during development. 
- IGF-1. Insulin-like growth factor I (IGF-I) stimulates 
proliferation of both oligodendrocyte progenitors and pre-OL O41 
positive cells, and IGF receptors have been shown to be present on cells 
of the oligodendrocyte lineage (84). IGF-I is also a potent survival 
factor for both oligodendrocyte progenitors and OLs in vitro. The 
morphology of myelinated axons and the expression of myelin specific 
protein genes have been examined in transgenic mice that overexpress 
IGF-I and in those that ectopically express IGF binding protein-1 
(IGFBP-1), a protein that inhibits IGF-I action when present in excess. 
The percentage of myelinated axons and the thickness of the myelin 
sheaths are significantly increased in IGF-I transgenics. An alteration in 
the number of OLs is seen but cannot completely account for the 
changes in the increase in myelin gene expression. IGFBP-1 transgenic 
mice have a decreased number of myelinated axons and thickness of 
the myelin sheaths. IGF-I could be involved in both the increase in OLs 
number and in the amount of myelin produced by each OL (85). 
- NT-3. Neurotrophin-3 (NT-3) is a mitogen for optic nerve 
oligodendroglial precursors only when added with high levels of 
insulin, with PDGF, or with their combination. Astrocytes express NT-
3 in optic nerve. NT-3 promotes also OL survival in vitro (86). The 
TrkC tyrosine kinase or TrkC receptor for NT-3 is expressed in OLs. 
Mice lacking NT-3 or its receptor TrkC exhibit profound deficiencies 
in CNS glial cells, particularly in oligodendrocyte progenitors; there is 
an important reduction in the spinal cord diameter, thereby suggesting 
that cell populations other than neurons are affected (87). 
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It was recently shown that NT-3 in combination with brain-
derived neurotrophic factor (BDNF) is able to induce proliferation of 
endogenous oligodendrocyte progenitors and the subsequent 
myelination of regenerating axons in a model of contused adult rat 
spinal cord (88). 
- GGF. The glial growth factor (GGF), a member of the 
neuregulin family of growth factors generated by alternative splicing, 
including Neu, heregulin, and the acetylcholine receptor-inducing 
activity (ARIA), is a neuronal factor, mitogenic on oligodendrocyte 
precursors; it is also a survival factor for these cells. It delays 
differentiation into mature OLs (89). In mice lacking the family of 
ligands termed neuregulins, OLs in spinal cord failed to develop (90). 
This failure can be rescued in vitro by the addition of recombinant 
neuregulin to explants of spinal cord. In the embryonic mouse spinal 
cord, neuregulin expression by motoneurons and the ventral ventricular 
zone is likely to exert an influence on early OPCs. Neuregulin is a 
strong candidate for an axon-derived promoter of myelinating cell 
development. 
- CNTF. The ciliary neurotrophic factor (CNTF) can also act 
as comitogen with PDGF. Animals deficient in CNTF have a reduced 
number of mitotic glial progenitors. CNTF also promotes OL survival 
in vivo (81). 
- IL-6. Interleukin (IL-6) may also act on OL survival as 
well as leukemia inhibitory factor (LIF) and a related molecule (91). 
- TGF-β. In vitro, transforming growth factor (TGF-β) 
inhibits PDGF-driven proliferation and promotes differentiation of 
oligodendrocyte progenitors (92). 
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1.3. Signaling pathways influencing growth and differentiation in several 
cell types 
1.3.1. Harvey-Ras/ Extracellular Signal-Regulated Kinases 1/2, H-RAS/ 
ERK 1/2 
The ERK 1/2 pathway is a signal transduction pathway that couples 
intracellular responses to the binding of growth factors to cell surface 
receptors. This pathway is very complex and includes many protein 
components. The pathway, described below, includes the major components 
of the basic pathway (Figure 7). In many cell types, activation of this pathway 
promotes cell division. 
 
 
Figure 7. The organization and function of the Ras–Raf–MEK–ERK pathway. 
 
Activated Ras activates the protein kinase RAF kinase; RAF kinase 
phosphorylates and activates MEK; MEK phosphorylates and activates the 
Extracellular-Regulated Kinase (ERK 1/2). 
RAF, MEK, and ERK 1/2 are all serine/threonine-selective protein 
kinases. 
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As discussed below, many additional targets for phosphorylation by 
ERK 1/2 were later found, and the protein was re-named "Mitogen-Activated 
Protein Kinase" (MAPK). The series of kinases from RAF to MEK to MAPK 
is an example of a protein kinase cascade. Such series of kinases provide 
opportunities for feedback regulation and signal amplification. 
H-Ras is localized at the cytoplasmic surface of the plasma membrane. 
It is a target of post-translational modification via attachment of farnesyl or 
methyl lipid moieties catalyzed by Farnesyltransferase (FTase) and 
Methyltransferase (ICMT), respectively. These post-translational 
modifications affect localization and biological activity of H-Ras (93). 
Like other G-proteins, H-Ras is found in two interconvertible forms, 
GDP-bound inactive and GTP-bound active. Conversion from GDP-bound 
form to GTP-bound is catalyzed by guanine nucleotide exchange factor 
(GEF). Activity of GEF is regulated by the upstream signals. GEFs that 
activate H-Ras are Son of Sevenless (SOS), PDZ-GEF1, CALDAG-GEF II 
and CALDAG-GEF III, RASGRF1, RASGRF2, and RasGRP4. 
GEF first interacts with the GDP-bound form and releases bound GDP. 
As a result, a binary complex of the small G protein and GEF is formed. Then 
GEF in this complex is replaced by GTP resulting in formation of the GTP-
bound small G protein (94). 
Conversion of GTP-bound form to GDP-bound form is a result of slow 
intrinsic GTPase activity of H-Ras. 
Proteins known as GTPase activated proteins (GAP) have been shown 
to stimulate this reaction. GAPs that inactivate H-Ras are p120GAP and 
RASA3. 
The activity of GEFs and GAPs is induced by a large variety of 
extracellular signals, most notably by those that activate receptors with 
intrinsic or associated tyrosine kinase activity. 
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The phosphotyrosines of the receptors, such as platelet-derived growth 
factor receptor beta (PDGF-R-β), serve as docking sites for the adaptor 
proteins, such as Src homology 2 domain containing transforming protein 
(Shc). Shc forms an adaptor protein complex with Growth factor receptor 
bound 2 (GRB2). This protein complex recruits SOS, the most characterized 
H-Ras-GEF, from the cytosol to produce a receptor-adaptor-GEF complex. 
G-protein-coupled receptors (GPCRs) can also activate H-Ras 
signaling. The β-1 adrenergic receptor binds to the PDZ-GEF1-leading to H-
Ras activation. 
Other receptors, RET proto-oncogene (RET) and TEK tyrosine kinase 
endothelial (TIE2), can directly activate Docking proteins 1 and 2 (DOK1 and 
DOK2). DOK1 and DOK2 in turn stimulate the GAP activity of p120GAP 
that down-regulate H-Ras signaling (95). In addition, cytoplasmic Ca
2+
 and 
second messenger 1,2-diacyl-glycerol (DAG) can activate calcium and DAG-
regulated GEFs (CALDAG-GEF II and CALDAG-GEF III). 
Major effectors of H-Ras protein are protein kinase v-Raf-1 murine 
leukemia viral oncogene homolog 1 (c-Raf-1) and Phosphatidylinositol 3-
kinase (PI3K cat class 1A). 
Small G-proteins are also known to cross-talk with each other. H-Ras 
activates guanine nucleotide exchange factors RalRGL and Tiam 1 that in 
turn activate small GTPases RalA and Rac1, respectively. 
 
1.3.2. Cyclic AMP Response Element Binding Protein, CREB protein 
CREB is a transcription factor; it binds to certain DNA sequences called 
cAMP response elements (CRE) and, thereby, increases or decreases the 
transcription of the downstream genes. CREB was first described in 1987 as a 
cAMP-responsive transcription factor regulating the somatostatin gene (96). 
Genes whose transcription is regulated by CREB include: c-fos, the 
neurotrophin BDNF, tyrosine hydroxylase, and many neuropeptides (such as 
 27 
somatostatin, enkephalin, VGF, and corticotropin-releasing hormone). CREB 
is closely related in structure and function to CREM (cAMP response element 
modulator) and ATF-1 (activating transcription factor-1) proteins. CREB 
proteins are expressed in many animals, including humans. CREB has a well-
documented role in neuronal plasticity and long-term memory formation in 
the brain (97). 
A typical (albeit somewhat simplified) sequence of events is as follows: 
a signal arrives at the cell surface, activates the corresponding receptor, which 
leads to the production of a second messenger, such as cAMP or Ca
2+
, which 
in turn activates a protein kinase. This protein kinase translocates to the cell 
nucleus, where it activates a CREB protein. The activated CREB protein then 
binds to a CRE region, and is then bound to by a CREB-Binding Protein 
(CBP), which coactivates it, allowing it to switch certain genes on or off. The 
DNA binding of CREB is mediated via its basic leucine zipper domain (bZIP 
domain). 
CREB can also be phosphorylated by a variety of kinases in response to 
mitogen, calcium and stress dependent signals. For instance, upon stimulation 
of cellular G-protein coupled receptors and growth factor receptors, adenylate 
cyclase is activated, leading to increases in cAMP. This in turn activates PKA 
by dissociating the regulatory from the catalytic subunits. Catalytic subunits 
can be translocated into the nucleus, where CREB is phosphorylated. The 
crucial event in the activation of CREB is the phosphorylation of Ser133 in 
kinase-inducible domain (KID). This domain includes several consensus 
phosphorylation sites for a variety of kinases [e.g. protein kinase A (PKA), 
protein kinase C (PKC), casein kinases, calmodulin kinases (CaMKs), 
glycogen synthase kinase-3, p34cdc2, p70s6k] that can either increase or 
decrease the activity of CREB. Phosphorylation on Ser133 promotes CREB to 
recruit transcriptional co-activators that induce transcription of a variety of 
intermediate early response genes. Dephosphorylation of Ser133 is important 
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for the inactivation of CREB. Both protein phosphatase 1 (PP-1) and PP-2A 
may be involved in the dephosphorylation of CREB. Based on the extent of 
homology at this region, members of the CREB family can be divided into the 
CREB, CREM, and activating transcription factor (ATF) groups (Figure 8). 
 
Figure 8. CREB Activation Pathways. 
CREB has many functions in many different organs, however most of 
its functions have been studied in relation to the brain. CREB proteins in 
neurons are thought to be involved in the formation of long-term memories; 
this has been shown in the marine snail Aplysia, the fruit fly Drosophila 
melanogaster, and in rats. CREB is necessary for the late stage of long-term 
potentiation. CREB also has an important role in the development of drug 
addiction (98). There are activator and repressor forms of CREB. Flies 
genetically engineered to overexpress the inactive form of CREB lose their 
ability to retain long-term memory. CREB is also important for the survival of 
neurons, as shown in genetically engineered mice, where CREB and CREM 
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were deleted in the brain. If CREB is lost in the whole developing mouse 
embryo, the mice die immediately after birth, again highlighting the critical 
role of CREB in promoting survival. 
Disturbance of CREB function in brain can contribute to the 
development and progression of Huntington's Disease. Abnormalities of a 
protein that interacts with the KID domain of CREB, the CBP is associated 
with Rubinstein-Taybi syndrome. CREB is also thought to be involved in the 
growth of some types of cancer. 
 
1.4. Markers of oligodendrocyte differentiation 
 
1.4.1. Oligodendrocyte Transcription Factor 2, Olig-2 
Oligodendrocyte transcription factor 2 (Olig-2) is a protein that in 
humans is encoded by the olig-2 gene. 
Olig-2 is a basic helix-loop-helix transcription factor. Its expression is 
predominantly restricted to the CNS. The protein is an essential regulator of 
ventral neuroectodermal progenitor cell fate and is required for OLs and 
motor neuron development. 
The olig-2 gene was originally discovered as a chromosomal 
translocation t(14;21)(q11.2;q22) associated with T-cell acute lymphoblastic 
leukemia (99). Its chromosomal location is within a region of chromosome 21 
which has been suggested to play a role in learning deficits associated with 
Down syndrome. 
Olig-2 is a universal marker of diffuse gliomas (oligodendroglioma, 
astrocytoma, glioblastoma, and mixed glioma). The expression in diffuse 
gliomas is distinct from other types of brain tumors and therefore is clinically 
useful as a pathologic marker for distinguishing these cancers. 
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1.4.2. Myelin Basic Protein, MBP 
The presence of the myelin sheath, a tightly packed multilamellar 
membrane, is crucial to the functioning of the vertebrate nervous system. 
Myelin is formed by specialized glial cells in both the CNS and PNS, and 
mutations in myelin components or autoimmune attack towards them leads to 
severe neurological defects. Many of the defects observed in dys- or 
demyelination can be attributed to potential disruption of the intimate 
interactions between myelin proteins and the myelin lipid bilayer (100). 
Interest in MBP has centered on its role in demyelinating diseases, in 
particular MS; several studies have shown a role for antibodies against MBP 
in the pathogenesis of MS which is characterized by the active degradation of 
the myelin sheath (101). Some studies have linked a genetic predisposition to 
MS to the MBP gene, though a majority have not. 
MBP is one of the most abundant proteins in myelin, and present at 
high concentration in both the CNS and PNS myelin (102, 103). MBP is a 
protein believed to be important in the process of myelination of nerves in the 
CNS. 
MBP is a peripheral membrane protein, which is reminiscent of 
intrinsically disordered proteins, when put into aqueous solution (104-106). 
Several lines of evidence, however, point towards a scenario, where 
interactions with ligands trigger secondary structure formation and some 
degree of folding into a more compact structure in MBP (107). 
MBP was initially sequenced in 1971 after isolation from myelin 
membranes (108). Since that time, knockout mice deficient in MBP that 
showed decreased amounts of CNS myelination and a progressive disorder 
characterized by tremors, seizures, and early death have been developed. The 
gene for MBP is on chromosome 18q22 (109) the protein localizes to the CNS 
and to various cells of the hematopoietic system. 
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The pool of MBP in the CNS is very diverse, with several splice 
variants being expressed and a large number of post-translational 
modifications on the protein, which include phosphorylation, methylation, 
deamidation, and citrullination. In melanocytic cell types, MBP gene 
expression may be regulated by MITF (110). 
 
 
1.4.3. α-Smooth Muscle Actin, α-SMA 
Actin is one of the most abundant and conserved protein in many 
eukaryotic cell types. It polymerizes forming microfilaments that have an 
array of functions including regulating contractility, motility, cytokinesis, 
phagocytosis, adhesion, cell morphology, and providing structural support. 
Six distinct actin isotypes, falling into three categories,have been 
identified in mammalian cells. The three types, separated based on isoelectric 
point, include α (α-Skeletal, α-Cardiac, α-Smooth Muscle), β (β -Non-muscle) 
and γ (γ-Smooth Muscle, γ-Non-Muscle) isoforms (111, 112). The actin 
isoforms are highly conserved at the amino acid level and only differ at their 
N-termini (112,113). 
Each is encoded by a separated gene and is expressed in a 
developmentally regulated and tissue-specific manner, α and β cytoplasmic 
actins are expressed in a wide variety of cells; whereas, expression of α-
skeletal, α-cardiac, α-vascular, and γ-enteric actins are more restricted to 
specialized muscle cell type. Expression of α-SMA is regulated by hormones, 
cell proliferation, and altered by pathological conditions including oncogenic 
transformation and atherosclerosis. 
The specific NH2-terminal sequence Ac-EEED of α-Smooth Muscle 
Actin (α-SMA or Acta2) plays an important role in the regulation of 
polymerization in vitro and in vivo (114). 
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1.5. Reactive Oxygen Species (ROS) and Oxidative stress 
For most living organisms, oxygen is an essential molecule for survival. 
Oxygen, in fact, is used as a terminal electron acceptor in the mitochondrial 
respiratory chain, leading to the synthesis of ATP needed for cellular 
metabolism. Almost all the oxygen used by mitochondria is reduced in the 
H2O molecule after accepting four electrons. The oxygen accepts one electron 
at a time, when it accepts the first electron, decreases superoxide radical 
(O2ˉ), the term indicates a radical molecular species with an unpaired electron 
in the last orbit and therefore extremely reactive. The superoxide radical can 
accept a second electron reducing further in hydrogen peroxide (H2O2) and 
molecular oxygen. This reaction is catalyzed by superoxide dismutase (SOD): 
 
2O2ˉ+2H
+→H2O2+O2 
 
Hydrogen peroxide in the presence of transition metal ions (i.e. Fe
2+/3+
, 
Cu
+/2+
), that are ions able to accept or donate electrons, changing their 
oxidation number, can be transformed into hydroxyl radical (OH) and 
hydroxyl ion (OHˉ) according to the Fenton reaction: 
Fe
2+
+H2O2→OH+ OHˉ+Fe
3+
 
These partially reduced forms of oxygen are called reactive oxygen 
species (ROS). 
The variety of ROS derived by both normal metabolic activities, both 
from the stresses generated by various mechanisms. 
These short-lived ROS can play physiological roles in signal 
transduction, but in excess can contribute to the mechanisms of disease by 
dysregulation of signal transduction and/or by oxidative damage to cellular 
macromolecules (lipids, proteins, DNA, RNA, carbohydrates) that exceeds 
the cellular capacity for regeneration or repair. As elaborated later under 
signal transduction, dysregulation of signal transduction and/or 
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macromolecular lesions can adversely alter cellular function or trigger 
apoptotic or necrotic cellular death. 
ROS are involved in many phenomena of damage to cell membranes, 
DNA and proteins with pathophysiological consequences of atherosclerosis, 
aging, and other degenerative disorders, but it is also true that free radicals are 
species that are produced by cells and as a result of the operation of the 
mitochondrial respiratory chain, both for the development of specific 
metabolic pathways necessary for the physiology of the cell, tissue and 
organism. ROS are generated by multiple pathways (Figure 9). The primary 
training site is the chain of mitochondrial electron transport, in fact, it is 
known that in this cellular compartment, 1,2% of electrons escape the chain of 
cytochromes and can go to reduce the oxygen superoxide (115). Due to the 
high concentration of SOD in the mitochondria, superoxide is converted into 
hydrogen peroxide. The latter is able to permeate the mitochondrial 
membrane (116) and reach the cytoplasm. 
Another source of intracellular ROS is the cytochrome P450 in the 
endoplasmic reticulum, in fact, it is known that cytochrome generates ROS 
during the oxidation of unsaturated fatty acids (117-119). ROS are also 
generated by the system hypoxanthine/xanthine oxidase, lipoxygenase and 
cyclooxygenase, in fact, use these free radicals to form prostaglandins, 
thromboxanes and leukotrienes. These factors regulate the formation of the 
clot and the recall of leukocytes at the site of inflammation. In the system 
hypoxanthine/xanthine oxidase, free radicals are used for the formation of 
uric acid during degradation of purines. Finally, the major source of ROS is 
Nicotinamide Adenine Dinucleotide Phosphate (NADPH)-oxidase. The 
NADPH oxidase is a multiprotein enzyme complex that catalyzes the 
production of O2ˉ from oxygen molecule: 
 
O2+NADPH→O2ˉ
.
+NADP
+
+H
+
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Figure 9. Sources of ROS. 
 
1.5.1. The NOX NADPH oxidases family 
The NOX-NADPH oxidases comprise a family of electron-transporting 
membrane enzymes family, whose primary function is the generation of ROS. 
ROS produced by NOX enzymes show a variety of biologic functions, such 
as microbial killing, blood pressure regulation, and otoconia formation. 
Strong evidence suggests that NOX enzymes are major contributors to 
oxidative damage in pathologic conditions. 
Whereas NOX2 (also known as gp91
phox
), the phagocyte oxidase, has 
been known for several decades as the enzyme responsible for the oxidative 
burst and associated microbicidal activity, the other members of the gene 
family have been identified only recently. The NOX family now consists of 
seven members (NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1, and 
DUOX2), each with a distinct tissue distribution. Since the discovery that 
NOX enzymes are not limited to white blood cells, an exponential increase in 
scientific reports describe how NOX enzymes are responsible for increased 
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ROS generation in numerous pathologic conditions, such as hypertension, 
ischemia/reperfusion, diabetes, cardiovascular diseases, and 
neurodegeneration. The elevated ROS production has been linked to the 
pathobiology of many of these conditions (120). The core catalytic domains 
of all seven NOX isoforms share similar structures, and their only known 
biochemical function is the generation of ROS. The basic catalytic subunit of 
NOX contains a C-terminal dehydrogenase domain featuring a binding site 
for NADPH and a bound flavin adenine nucleotide (FAD), as well as an N-
terminal domain consisting of six transmembrane alpha helices that bind two 
heme groups. On activation, cytosolic NADPH transfers its electrons to the 
FAD, which in turn passes electrons sequentially to the two hemes and 
ultimately to molecular oxygen on the opposing side of the membrane, to 
form the superoxide anion (O2ˉ
.
) (121). 
Although all seven NOX isoforms catalyze the reduction of molecular 
oxygen, they differ in their tissue distribution, their subunit requirements, 
domain structure, and the mechanism by which they are activated. In the case 
of NOX2, the activation mechanism is well described: on activation, the 
regulatory subunit p47
phox
 is phosphorylated and translocates to the 
membrane, in the form of a complex that also contains p67
phox
 and p40
phox
. 
Once at the membrane, the cytosolic complex binds to the transmembrane 
cytochrome unit comprising both NOX2 and the closely associated p22
phox
. 
Independently, the GTP-binding protein Rac also moves to the membrane, 
and the combination of regulatory subunits induces activation. Like NOX1, 
NOX2 and NOX3 require p22
phox
, as well as association with cytosolic 
regulatory components (p47
phox
/p67
phox
 or their homologues NOXO1, 
NOXA1) p40phox and Rac. NOX4 requires p22
phox
, but not the cytosolic 
regulatory factors (122). NOX5 and the DUOXes are activated by elevation of 
intracellular Ca
2+
, which binds directly to N-terminal EF-hand domains (123). 
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1.5.2. Regulation of NADPH oxidase 
Several lines of evidence support a role of PKC in NADPH oxidase 
activation. PMA, an activator of PKC, is a strong stimulus of O2ˉ
.
 production 
in whole cells. Purified p47
phox
 is a good substrate for PKC in vitro. 
Staurosporine, a powerful inhibitor of PKC, inhibits superoxide production 
and p47
phox
 phosphorylation. The data presented here provide clear evidence 
that, in addition to p47
phox
, p67
phox
 itself could play a role in the regulation of 
NADPH oxidase by phosphorylation/dephosphorylation reactions and that the 
phosphorylation events involve a PKC-dependent pathway. Little is known of 
the possible role of other protein kinases in the regulation of NADPH oxidase. 
It has been suggested that cyclic AMP-dependent protein kinase, MAPK, and 
p21-activated kinase could regulate NADPH oxidase by phosphorylating 
p47
phox
 and that protein kinases other than PKC may participate in p67
phox
 
phosphorylation (124). 
1.6. Relationship between oxidative stress and Multiple Sclerosis 
Diseases that result in injury to the oligodendroglial cells include 
demyelinating diseases such as MS and leukodystrophies in the CNS and 
peripheral neuropathies in the PNS. Cerebral palsy (periventricular 
leukomalacia) is caused by damage to developing OLs in the brain areas 
around the cerebral ventricles. Spinal cord injury also causes damage to OLs 
(125). In cerebral palsy, spinal cord injury, stroke and possibly MS, OLs are 
thought to be damaged by excessive release of the neurotransmitter glutamate. 
OLs dysfunction may also be implicated in the pathophysiology of 
schizophrenia and bipolar disorder (126). Oligodendroglia are also susceptible 
to infection by the JC virus (Human polyomavirus), which causes progressive 
multifocal leukoencephalopathy (PML), a condition that specifically affects 
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white matter, typically in immunocompromised patients. Tumors of 
oligodendroglia are called oligodendrogliomas. 
Recently, it has been shown that the production of ROS can be involved 
in the pathogenesis of several diseases affecting the CNS (127, 128). Our 
research group for several years have been studying the cellular and 
molecular mechanisms of redox signal transduction in several conditions 
(129, 130), such as systemic sclerosis (scleroderma), neuronal degeneration, 
and ischemia/cerebral and renal reperfusion. Specifically, we have found that 
in systemic sclerosis redox signalling is hypertrophic in immune cells and 
fibroblasts (131, 132). We wished to apply some of the findings in systemic 
sclerosis to MS and specifically, the molecular mechanism linked to oxidative 
stress in MS. The OLs and their precursors are very sensitive to oxidative 
stress, because they use large amounts of oxygen. They also have a reduced 
antioxidant defence system and a high intracellular concentration of Fe ions 
(133). This sensitivity is inversely correlated to the maturation level, in fact 
the OLs precursors show an increased in susceptibility to oxidative stress, 
compared to mature cells (134). 
MS is a chronic demyelinating disease of CNS in which inflammatory 
processes and neurodegeneration contribute to demyelination and axonal 
damage. There are important experiments about the involvement of oxidative 
stress in the pathogenesis of this disease. The OLs and their precursors are, in 
fact, highly sensitive to oxidative stress, because of the large amounts of 
oxygen consumed, low levels of cellular antioxidant defense systems and high 
intracellular iron content (133). 
In MS it is not known whether the remyelination is slowed or blocked. 
Failure in remyelination in MS has been associated with limited availability 
or migratory capacity of OPCs. In fact, in chronic demyelinating lesions it 
was observed a small number of mature cells and an increased number of 
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precursors, suggesting the presence of a block of the maturation process of 
OPCs. The intracellular redox state, regulated by extracellular signal 
molecules, is able to modulate the balance between self-renewal and 
differentiation in dividing cells (135). Therefore, alterations of cellular redox 
state in MS may represent a pro-apoptotic stimulus to OLs, but also can affect 
differentiation processes of OPCs resulting in demyelination. 
 
1.6.1. Oxidative stress in oligodendrocytes 
Cellular proliferation and differentiation in the nervous system are 
closely linked processes, controlled by a number of growth factors and 
depend on environmental conditions. In tissue culture, serum addition 
provides neural cells with necessary extrinsic growth factor supplements that 
promote cell growth and enable survival. 
Serum deprivation, on the other hand, causes an arrest in cell division 
and may induce cellular differentiation. 
Extended periods of serum deprivation may eventually lead to cell 
death due to the lack of growth factors or increased oxidative stress. 
Cells in the nervous system are highly sensitive to oxidative stress 
because they utilize high levels of oxygen for normal function, and the brain 
has relatively poorly developed antioxidant mechanisms (136-138). 
OLs and their precursor cells exhibit a high sensitivity to oxidative 
stress. Oligodendrocyte precursors, for example, are easily damaged by 
hypoxic events because of low antioxidant levels and high iron content. The 
cytotoxic potential of oxygen radical-generating systems on bovine OLs 
prepared from adult brains was described. Maturation-dependent differences 
in the vulnerability of OLs to oxidative stress are observable, specifically 
oligodendrocyte precursors show a higher sensitivity to oxidative stress-
induced death caused by glutathione depletion. There is little information at 
the present time on the effects of toxic radicals on the molecular mechanisms 
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regulating cell survival and death in proliferating compared to differentiating 
oligodendroglia cells (139). 
The molecular mechanisms underlying H2O2-induced toxicity were 
characterized in rat oligodendrocyte cultures. While progenitor cells were 
more sensitive than mature OLs to H2O2, the antioxidant, N-acetyl-L-cysteine 
(NAC), blocked toxicity at both stages of development. As free radicals have 
been considered to serve as second messengers, was examined the effect of 
H2O2 on activation of the MAPK, ERK1/2 and p38. H2O2 caused a time and 
concentration-dependent increase in MAPK phosphorylation, an effect that 
was totally blocked by NAC. Further exploration of potential mechanisms 
involved in oligodendrocyte cell death showed that H2O2 treatment caused 
DNA condensation and fragmentation at both stages of development, whereas 
caspase 3 activation and poly (ADP-ribose) polymerase cleavage were 
significantly increased only in oligodendrocyte progenitors. The pan-caspase 
inhibitor, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, blocked 
DNA fragmentation in progenitors and produced a small but significant level 
of protection from H2O2 toxicity in progenitors and mature OLs. In contrast, 
inhibitors of both p38 and MEK reduced H2O2-induced death most 
significantly in OLs. The poly (ADPribose) polymerase inhibitor, PJ34, 
reduced H2O2-induced toxicity on its own but was most effective when 
combined with benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone or 
PD169316. The finding that molecular mechanisms conferring resistance to 
reactive oxygen species toxicity are regulated during oligodendrocyte 
differentiation may be of importance in designing therapies for certain 
neurological diseases affecting white matter (134). 
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CHAPTER II 
OBJECTIVES 
 
The balance between cell proliferation and differentiation is controlled 
by opposing cellular signals that modulate important cell functions as 
development, tissue repair, and tissue homeostasis; yet relatively little is 
known about physiological mechanisms central to such modulation. 
It has been shown that redox state of the OLs is modulated by 
extracellular signaling molecules that alter the balance between self-renewal 
and differentiation: growth factors that promote self-renawal cause 
progenitors to became more reduced, while signaling molecules that promote 
differentiation cause progenitors to became more oxidized (135). 
The correlation of cellular redox state with differentiation of OPCs is of 
great interest; however, it is not known whether this correlation is 
coincidental or whether it provides an important cue to understanding the 
molecular mechanisms inducing OLs to differentiate in mature myelinating 
cells. 
The objectives of present thesis project are: 
 the evaluation of ROS importance as OLs differentiation 
mediators. 
To this end we used M03-13 cells, an immortal human cell line that 
expresses phenotypic characteristics of primary OLs. Under appropriate 
conditions, these cells are able to differentiate in mature OLs. 
We first will consider the effects of a differentiation stimulus, Phorbol-12-
Myristate-13-Acetate (PMA, an activator of PKC), in medium deprived of 
serum, on the appearance of early and late differentiation markers such as 
ERK1/2, P-CREB, MBP, α-SMA and Olig-2. Secondly, we will expose the 
cells to low doses of H2O2 to test if ROS modify differentiation, by 
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measuring the differentiation markers levels modulated by the PMA 
stimulus. 
 the analysis of signal transduction pathways involved in the 
modulation of differentiation, mediated by PMA and/or H2O2. 
Our group, for several years, has been studying signal transduction 
pathways linking membrane receptors to various transducers, including 
p21Ras and cAMP. We have shown that Ras isoforms, Ha-Ras and Ki-Ras, 
have opposing functions in regulation of redox signals. Ha-Ras-expressing 
cells produce high levels of ROS by inducing the NADPH-oxidase system. 
Ki-Ras, on the other hand, stimulates the scavenging of ROS by activating 
post-trascriptionally the mytochondrial antioxidant enzyme, Mn-superoxide 
dismutase (Mn-SOD), via an ERK1/2-dependent pathway (58). Ras proteins 
are exquisite redox sensors, that adapt the cell to various metabolic needs 
following receptor stimulation. We have shown that the levels of Ras proteins 
in human primary fibroblasts are regulated by citokynes, such as PDGF. 
PDGF stabilizes Ha-Ras by stimulating ROS and ERK1/2. Activation of 
ERK1/2 and high ROS levels stabilize Ha-Ras protein, by inhibiting 
proteasomal degradation. We found a remarkable example in vivo of 
amplification of this circuit in fibroblasts derived from systemic sclerosis 
(scleroderma) lesions, producing vast excess of ROS and undergoing rapid 
senescence. High ROS, Ha-Ras, and active ERK1/2 stimulated collagen 
synthesis, DNA damage, and accelerated senescence. Conversely ROS or Ras 
inhibition interrupted the signaling cascade and restored the normal 
phenotype. In primary cells, stabilization of Ras protein by ROS and ERK1/2 
amplifies the response of the cells to growth factors. In some autoimmune 
diseases, such as scleroderma, this represents a critical factor in the onset and 
progression of the disease (131). In this disease there are stimulatory 
autoantibodies against PDGF-R, which appear to be a specific hallmark of 
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scleroderma. Their biologic activity on fibroblasts strongly suggests that they 
have a causal role in the pathogenesis of the disease (132). 
Starting from these findings, and since the cause and definitive therapy 
of the MS are still unknown, we wish to explore the possibility that such a 
circuit exists also in MS. We wish to use the OLs as tester cell system to 
explore the presence of molecules that interfere with their differentiation. 
So we will study in OLs, in presence of the differentiation stimulus, the 
effects of stimulation with CSF or Ig, extracted from the serum of patients 
affected by MS, on cellular redox state and maturation processes 
(differentiation block). 
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CHAPTER III 
MATERIALS AND METHODS 
 
3.1. Cell cultures 
M03-13 CELLS - The M03-13 cells are an immortal human-human 
hybrid cell line with the phenotypic characteristics of primary OLs, derived 
from the fusion of a 6-thioguanine-resistant mutant of a human 
rhabdomyosarcoma with OLs obtained from adult human brain. They were 
grown in Dulbecco’s Modified Eagles Medium (DMEM; GIBCO Invitrogen), 
containing 4.5g/L glucose (GIBCO, Auckland, New Zealand), supplemented 
with 10% Foetal Bovine Serum (FBS; Sigma S. Louis, USA), 100 U/ml 
penicillin and 100 μg/ml streptomycin. The cells were kept in a 5% CO2 and 
95% air atmosphere at 37° C. 
The cells were differentiated in FBS-free DMEM, supplementing with 
100 nM of Phorbol-12-Myristate-13-Acetate (PMA; Sigma-Aldrich). The 
cells were kept in a 5% CO2 and 95% air atmosphere at 37° C for 30 minutes, 
or 1day (pro-differentiation conditions) or 4 days (mature OLs). The 
differentiated cells express markers of mature OLs such as MBP, 
Proteolipidic Protein (PLP) and 2’,3’-cyclic nucleoside 3’-phosphodiesterase 
(CNPasi). These cells represent an excellent model to study the maturation 
and differentiation process of oligodendrocyte precursors. 
HEK293 CELLS - HEK293 is a cell line derived from human 
embryonic kidney cells, of a healthy, aborted fetus, grown in tissue culture. 
This particular line was initiated by the transformation and culturing of 
normal HEK cells with sheared adenovirus 5 DNA. The transformation 
resulted in the incorporation of approximately 4.5 kilobases from the viral 
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genome into human chromosome 19 of the HEK cells. Cells were grown in 
Dulbecco’s Modified Eagles Medium (DMEM; GIBCO Invitrogen), 
containing 4.5g/L glucose (GIBCO, Auckland, New Zealand), supplemented 
with 10% FBS (Sigma S. Louis, USA), 100 U/ml penicillin and 100 μg/ml 
streptomycin. The cells were kept in a 5% CO2 and 95% air atmosphere at 
37°C. 
3.2. Flow cytometric assay of cell viability 
The toxicity of H2O2 treatment was tested by cytofluorimetric analysis of 
Propidium Iodide (PI) staining of treated and control M03-13 cells 
differentiated with PMA (100nM) for 4 days. These cells, plated in 35mm 
Petri dishes and grown to semi confluence, were treated with increasing doses 
of H2O2 (200, 400, 600, 800, 1000μM) for 18 hours in medium without 
serum. After trypsinization and wash in PBS, the cells were resuspended in 
500μl of PBS and 1μgr/ml of PI was added before the flow cytometric 
analysis of PI-positive cells performed with a FCSscan apparatus (Becton-
Dickinson). Data were analyzed using WinMDI 2.8 software. 
3.3. H2O2 treatments 
M03-13 cells, grown to semi confluence in 60mm dishes in FBS-free 
DMEM 4.5g/L glucose, supplementing with 100nM of PMA for 4 days, were 
stimulated for 30minutes with decreasing concentrations (starting from non 
toxic dose of 200μM, 50 and10 μM) of H2O2. Afterwards, it was used a H2O2 
concentration that in the cell viability assay didn’t show a significant 
stimulation of apoptosis and at the same time induced modulation, analyzed 
by Western-blot, of differentiation markers. 
M03-13 cells, grown to semi confluence in 60mm dishes in DMEM 
4.5g/L glucose, were stimulated with H2O2 (200μM). The cells were kept in a 
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5% CO2 and 95% air atmosphere at 37° C for 1day or 4 days and after the 
differentiation markers were analyzed by Western-blot, confocal microscopy, 
or by flow cytometric analysis. 
3.4. Inhibitors treatment 
APOCYNIN:1-(4-Hydroxy-3-methoxyphenyl)ethanone, also known as 
apocynin or acetovanillone, is a natural organic compound structurally related 
to vanillin. 
M03-13 cells, preincubated for 1 hour with Apocynin (50μM, Sigma-
Aldrich) were stimulated for 4 days with PMA (100 nM) or with H2O2 
(200μM). 
BISINDOLYLMALEIMIDE: Bisindolylmaleimide VIII acetate is a 
selective inhibitor of PKC. 
M03-13 cells, preincubated for 30minutes with Bisindolylmaleimide 
(BIM, 100μM, Sigma-Aldrich) were stimulated for 4 days with PMA (100 
nM) or with H2O2 (200μM). 
PD98059: 2′-Amino-3′-methoxyflavone is a selective, reversible, and 
cell-permeable inhibitor of MEK, that acts by inhibiting the activation of 
MAP kinase and subsequent phosphorylation of MAP kinase substrates.  
M03-13 cells, preincubated for 30minutes with PD98059 (PD, 40μM, 
Calbiochem) were stimulated for 4 days with PMA (100 nM) or with H2O2 
(200μM). 
 
3.5. Patients 
In the study were included men and women between 15 and 50 years of 
age who meet all the following criteria: 
 diagnosis of relapsing/remitting MS, according to McDonald criteria; 
 an Expanded Disability Scale Score (EDSS) between 0 and 5.0; 
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 lesions detected by MRI compatible with the diagnosis of MS; 
 at least one acute episode in the last 12 months. 
The control subjects are patients with neurological diseases that need 
differential diagnosis with MS (cerebral cancers, stroke, vasculitis, etc.) 
selected by sex and age similar to MS patients. 
All the patients were subjected to CSF collection by lumbar puncture to 
execute the routine laboratory analysis in the hospital where they were 
hospitalized. A quantity of 1-2ml of CSF was sent to our laboratories to carry 
out the investigations of our interest. At the same time a blood sample, from 
each patients, was collected to purify the IgG fractions from blood serum. 
The hospitals that have collaborated to our project are: 
 Cardarelli Hospital, Naples -Department of Neurology- Dr. C. Florio; -
Department of Neurophysiopathology- Dr. F. Habetswallner; 
 Polyclinic Federico II University, Naples -Department of Neurology- 
Prof. Orefice. 
3.6. Cerebrospinal fluid treatment 
To analyze the cell maturation processes in response to CSF stimulation 
the M03-13 cells, grown in FBS-free DMEM 4.5g/L glucose, supplementing 
with 100nM of PMA, were stimulated with CSF (30% v/v) from MS patients 
and control group for 1 or 4 days. The differentiation markers were analyzed 
by Western-blot or by confocal microscopy. 
3.7. Purification of Immunoglobulins 
The purification of IgG fractions from serum of MS and control 
subjects will be carried out by affinity chromatography on A/G Sepharose 
columns (Pierce, Rockford, IL). The protein concentration of immunoglobulin 
fractions thus prepared will be assessed spectrophotometrically and used in 
oligodendrocyte differentiation cell models. 
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3.8. Immunoglobulins treatment 
To check the effect of IgG fractions stimulation on the molecular 
mechanisms related to oxidative stress in OLs and on the cell maturation 
processes, the M03-13 cells, grown in FBS-free DMEM 4.5g/L glucose, 
supplementing with 100nM of PMA, were stimulated with 200µg/ml of serum 
IgG from MS patients and control group for 1or 4 days. The differentiation 
markers were analyzed by Western-blot or by confocal microscopy. 
3.9. Protein extraction 
The RIPA buffer was used to extract the proteins from mammalian 
cells. A cocktail of protease inhibitors (Roche, USA) was added to the buffer 
to prevent the protein degradation during the extraction procedure. 
RIPA buffer: 
 50 mM Tris-HCl, pH 7.5 
 150 mM NaCl 
 1% NP-40 
 0.5% Deoxycholic acid (DOC) 
 0.1% Sodium Dodecil Sulfate (SDS) 
 2.5mM Sodium Pyrophosphate (SPP) 
 1mM β-Glycerophosphate  
 1mM Sodium Orthovanadate (NaVO4) 
 1mM Sodium Fluoride (NaF) 
 Protease inibitor (1X) 
 0.5mM Phenyl-methane-sulfonyl-fluoride (PMSF)  
The cells were detached from the dishes with a scraper using the RIPA 
buffer in appropriate doses depending on the number of cells (100μl RIPA 
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buffer per 5 · 10
5
 cells), on ice. Then, to achieve a complete lysis, cells were 
kept for 15min at 4°C and disrupted by repeated aspiration (for approximately 
10 times) through a 21-gauge needle. The extract preparations were 
centrifuged at 13000 rpm for 15 minutes at 4° C and the pellets were 
discarded. The Lowry protein assay was used to determine the protein 
concentration. 
 
3.10. Protein determination 
The Lowry protein assay was used for determining the total level of 
protein in a solution. The total protein concentration is exhibited by a color 
change of the sample solution in proportion to protein concentration, which 
can then be measured using colorimetric techniques. It is named for the 
biochemist Oliver H. Lowry who developed the technique in the 1940s. His 
1951 paper describing the technique is among the most-highly cited papers in 
biology. The method combines the reactions of cupric ions with the peptide 
bonds under alkaline conditions (the Biuret test) with the oxidation of 
aromatic protein residues. The Lowry method is best used with protein 
concentrations of 0.01-1.0 mg/mL and is based on the reaction of Cu
+
, 
produced by the oxidation of peptide bonds, with Folin-Ciocalteu reagent (a 
mixture of phosphotungstic acid and phosphomolybdic acid in the Folin-
Ciocalteu reaction). The reaction mechanism involves reduction of the Folin 
reagent and oxidation of aromatic residues (mainly tryptophan, also tyrosine). 
The concentration of the reduced Folin reagent is measured by absorbance at 
660 nm. As a result, the total concentration of protein in the sample can be 
deduced from the concentration of Trp and Tyr residues that reduce the Folin 
reagent. A reference standard was performed on four samples with increasing 
concentrations of Bovine Serum Albumin (BSA). 
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3.11. Western-blotting analysis 
50 μg of total cells lysates were subjected to SDS-PAGE under 
reducing conditions using precast gels 4-12% gradient (Invitrogen). The 
protein samples were heated at 70º C and loaded on the gel. After 
electrophoresis, the proteins were transferred onto a PDVF filter membrane 
(Invitrogen) with a Trans-Blot Cell (Invitrogen) and transfer buffer containing 
25 mM Tris, 192 mM glycine, 20% methanol. The transfer was carried out at 
4°C for 75 minutes at 40V. Membranes were placed in Blocking buffer 
(Invitrogen) at 4° C over-night to block the nonspecific binding sites. Filters 
were incubated with specific antibodies before being washed two times in 
water. Then, the filter was washed with wash buffer 3 times for 5 minutes and 
incubated with a peroxidase-conjugated secondary antibody (Invitrogen). 
After washing with wash buffer, peroxidase activity was detected with the 
ECL (Enhanced ChemiLuminescence) system (Invitrogen). 
The filters were also probed with an anti -Tubulin antibody (Sigma, 
USA). Protein bands were revealed by ECL and, when specified, quantified 
by densitometry using ScionImage software. Densitometric values were 
normalized to -Tubulin. 
3.12. Flow cytometric analysis of Mielin Basic Protein 
Cells were grown to semiconfluency in 60-mm culture dishes. After 
trypsin detachment, 5 · 10
5
 cells are suspended in 1 mL of phosphate buffered 
saline (PBS) and fixed overnight with 1% formaldehyde at room temperature. 
Next, cells were permeabilized with 0.1% Triton X-100 for 40 min at 4°C, 
washed 4x with PBS containing 2% FBS, 0.01% NaN3, 0.1% Triton X-100 
(buffer A), and incubated for 45 min at 4° C with 1:50 dilution of rabbit 
polyclonal anti-human MBP Ig. The cells were then washed twice with the 
same buffer and incubated for 45 min at 4°C with Cy3-conjugated anti-(rabbit 
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IgG) Ig at 1:50 dilution. Control cells were incubated with Cy3-conjugated 
anti-(rabbit IgG) Ig alone. After two washes in buffer A, cells were 
resuspended in PBS and analyzed by flow cytometry using FACSCAN (BD, 
Heidelberg, Germany) and WINMDI software. 
3.13. Immunofluorescence confocal microscopy 
MBP AND ALPHA-SMA: M03-13 cells were grown on glass coverslip 
under culture conditions decribed in the specific experiments. Then, the 
medium was removed and cells immediately fixed in 3.7% Paraformaldehyde 
in PBS with 2% Sucrose, pH 7.4, for 5 min at 22°C, and, after 2 washes in 
PBS with 2% Sucrose, permeabilized for 10 min at 4°C with 0.01% Saponin 
(Sigma-Aldrich, from quillaja bark) in PBS. 
The cells, after blocking with 20% FBS in PBS with 0.01% Saponin for 
30 minutes at 4°C, were labelled with primary rabbit-polyclonal anti human 
MBP antibody or with primary mouse-polyclonal anti human α-SMA 
antibody. The cells were washed and labelled with secondary Cy3-conjugated 
anti-rabbit IgG (Jackson ImmunoResearch, USA) or with secondary Cy2-
conjugated anti-mouse IgG (Jackson ImmunoResearch, USA). Controls were 
incubated with secondary antibodies alone. After treatment with nuclear 
marker, 4',6-diamidino-2-phenylindole (DAPI), the coverslips were briefly 
washed first, in PBS and then in distilled water, and finally mounted on glass 
slides for microscopy examination. Cells were analyzed with a Zeiss LSM 
510 Meta laser scanning confocal microscope. 
OLIG-2: M03-13 cells were grown on glass coverslip under culture 
conditions decribed in the specific experiments. Then, the medium was 
removed and cells immediately fixed in 3.7% Paraformaldehyde in PBS with 
2% Sucrose, pH 7.4, for 5 min at 22°C, and, after 2 washes in PBS with 2% 
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Sucrose, permeabilized for 5 min at 4°C with 0.1%Triton X-100 in 20mM 
Hepes, 300mM Sucrose, 50mM NaCl, 3 mM MgCl2. 
The cells, after blocking with 20% FBS in PBS for 30 minutes at 4°C, 
were labelled with primary rabbit polyclonal anti human Olig-2 antibody. The 
cells were washed and labelled with secondary Cy3-conjugated anti-rabbit 
IgG (Jackson ImmunoResearch, USA). Controls were incubated with 
secondary antibodies alone. After treatment with nuclear marker, 4',6-
diamidino-2-phenylindole (DAPI), the coverslips were briefly washed first, in 
PBS and then in distilled water, and finally mounted on glass slides for 
microscopy examination. Cells were analyzed with a Zeiss LSM 510 Meta 
laser scanning confocal microscope. 
Afterwards, images were analysed using the ImageJ software: we set 
the threshold on the maximum fluorescent value of the sample treated only 
with secondary antibody, and quantified 25cells for each sample. Regions of 
interest (ROI) were defined to restrict the analysis to a spatially confined 
cellular area. 
3.14. Real Time PCR analysis 
RNA isolation and real-time PCR were performed as follow: total RNA 
was extracted using TRI-reagent according to the protocol provided by the 
manufacturer (Sigma, USA). Total RNA (4 µg) was reverse transcribed with 
Omniscript Reverse Transcriptase (Quiagen, USA) by oligo-dT primers for 60 
min at 37°C in 40 µl reaction volumes. Real-time PCR was performed with an 
ABI 5700 or ABI PRISM-7900HT Sequence Detection System (Applied 
Biosystems Inc., USA). Reactions were carried out in 96-well optical reaction 
plates in a 50 µl final volume containing 25 µl of the SYBR-Green (Applied 
Biosystems Inc., USA) PCR master mix, 1,25 µl of each gene-specific primer, 
40 ng of sample cDNA. Gene-specific primers were designed to selectively 
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amplify -SMA and relative expression values were normalized using 
glucose-6-phosphate dehydrogenase (G6PD). The SYBRGreen (Applied 
Biosystems Inc., USA) fluorescence was measured at each extension step. 
The threshold cycle (Ct) value reflects the cycle number at which the 
fluorescence measurement reached an arbitrary threshold. Melting curve 
analysis was performed to determine the specificity of the reaction. Real-time 
PCR was conducted in triplicate for each sample and the mean value was 
calculated. 
Primers for human -SMA and G6PD used are the following: 
--SMA Forward: CTG TTC CAG CCA TCC TTC AT; 
 -SMA Reverse: TCA TGA TGC TGT TGT AGG TGG T;  
-Human G6PD Forward: ACA GAG TGA GCCC TTC TTC AA; 
 Human G6PD Reverse: ATA GGA GTT GCG GGC AAA G 
 
3.15. Statistical analysis 
Statistical differences were evaluated using a Student’s t-test for 
unpaired samples. 
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CHAPTER IV 
RESULTS 
 
4.1. Effects of PMA on oligodendrocyte differentiation 
M03-13 cells were exposed to PMA 100nM in medium without serum 
for 4 days. Figure 10, an optical microscope image, shows the morphological 
changes of the differentiated compared to control cells: the differentiating 
cells are no longer motile and extend multiple processes. 
 
 
Figure 10. Optical microscope image. 
M03-13 undifferentiated (Undiff. M03-13) and differentiated (Diff. M03-13) for 4 days 
with PMA 100nM in the absence of serum. 
 
We first analyzed the effects of 30minutes exposure to 100nM PMA, in 
cells pre-incubated for 16 hours in a medium containing 0.2% FBS, on 
signaling molecules (P-ERK1/2 and P-CREB) involved in OLs differentiation 
and also on a negative differentiation marker, α-SMA. In fact, FGF2-mediated 
OL induction is dependent on MAP kinase signalling and is inhibited by 
BMP4; E14 rat dorsal spinal cord cultures, treated by BMP4, show a dose-
dependent reduction of OLs and astrocytes, and an induction of SMA. 
Therefore OLs differentiation is accompanied by significant reduction of SMA 
(140). Differentiation induced by PMA decreased -SMA protein levels and, 
instead, increased P-ERK1/2 and P-CREB levels (Figure 11). 
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Figure 11. Modulation of -SMA, P-ERK1/2 and P-CREB levels in M03-13 cells 
stimulated with PMA for 30min. 
The cells were incubated for 16 hours in medium containing 0.2% of FBS (Ctr) and then 
stimulated with 100nM PMA in medium without serum for 30min before harversting them 
for Western blotting analysis of -SMA, P-ERK1/2 and P-CREB levels. The histogram 
shows the values (means  SEM) relative to control obtained by densitometric analysis of 
protein bands normalized to -Tubulin in three independent experiments. *p<0.01 vs Ctr. 
 
Moreover, we measured the expression of -SMA, P-ERK1/2 and P-
CREB protein levels after 1 day of treatment with 100nM PMA in the absence 
of serum. As it is shown in Figure 12, differentiation of the cells is 
accompanied by a reduction of -SMA levels. On the contrary, P-ERK1/2 and 
P-CREB levels are induced by differentiation. 
 
Figure 12. Modulation of -SMA, P-ERK1/2 and P-CREB levels in M03-13 cells 
stimulated with PMA for 1d. 
Western blotting analysis of -SMA, P-ERK1/2 and P-CREB levels in M03-13 cells after 1 
day of differentiation of M03-13 cells with 100nM PMA in medium without serum. N.D. 
indicates Not Differentiated cells, growing in complete medium. 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of protein bands normalized to -Tubulin in three independent 
experiments. *p<0.01 vs N.D. 
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The levels of MBP were, then, evaluated by flow cytometry at 1 and 4 
days of differentiation with PMA. Figure 13 shows that PMA 100nM in 
medium without serum induces a time-dependent increase of MBP protein 
levels. 
 
Figure 13. Increasing levels of MBP protein at different days of differentiation of 
M03-13 cells with PMA. 
Immunoreactivity for MBP was evidenced by indirect immunofluorescence and flow 
cytometry, using primary antibodies against MBP and CY3-conjugated anti rabbit IgG as 
secondary antibodies. Control was treated with secondary antibodies alone. 10,000 cells 
were counted for each sample. N.D. indicates Not Differentiated cells, growing in 
complete medium. A sample of cells differentiated for 4 days with 100nM PMA in 
medium without serum is also shown (Diff.). 
The histogram shows the mean  SEM in three independent experiments. *p<0.01 vs N.D. 
 
Afterwards we considered the expression of -SMA, P-ERK1/2 and P-
CREB in M03-13 cells after several days of 100nM PMA treatment in the 
absence of serum. 
Figure 14 shows that P-CREB levels are induced by differentiation, with a 
peak at 1 day; conversely, a progressive decrease of -SMA levels is observed 
in differentiated cells. 
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Figure 14. P-CREB and -SMA levels in M03-13 cells during differentiation with 
PMA. 
Western blotting analysis of P-CREB and -SMA levels in M03-13 cells after 1, 2 and 4 
days of differentiation of M03-13 cells with 100nM PMA in medium without serum. N.D. 
indicates Not Differentiated cells, growing in complete medium. 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of protein bands normalized to -Tubulin in three independent 
experiments. *p<0.01 vs N.D. 
 
Figure 15 shows that P-ERK1/2 levels are progressively induced by 
differentiation. 
 
 
Figure 15. Western blotting analysis of P-ERK1/2 levels in M03-13 cells after 
different days of differentiation with 100nM PMA in a medium without serum. 
Western blotting analysis of P-ERK1/2 levels in M03-13 cells after 1, 2 and 4 days of 
differentiation of M03-13 cells with 100nM PMA in medium without serum. N.D. 
indicates Not Differentiated cells, growing in complete medium. 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of protein bands normalized to -Tubulin in three independent 
experiments. *p<0.01 vs N.D. 
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4.2. Effects of oxidative stress on growth and differentiation of 
         oligodendrocytes 
To find a correlation between cellular redox state and differentiation of 
OPCs, we evaluated the effects of H2O2 on differentiation markers in M03-13 
cells. 
To monitor the effects of H2O2 on M03-13 cell survival, we induced 
differentiation in FBS-free DMEM, supplemented with 100 nM of PMA for 4 
days and then treated the cells with increasing doses of H2O2 (200, 400, 800, 
1000μM) for 18 hours. Flow-cytometric analysis of PI-positive cells shown 
an increase of cell death by high H2O2 doses (from 400μM to 1000 μM) 
compared to control cells, while M03-13 cells treated with a 200μM H2O2 did 
not show significant cell death (Figure 16). 
 
Figure 16. Dose-dependent effect of H2O2 on cell viability. 
The MO3-13 cells were differentiated in FBS-free DMEM supplementing with 100 nm of 
PMA for 4 days; the cell viability after stimulation with increasing doses of H2O2 was 
measured by cytofluorimetry with Propidium Iodide (PI) staining.  
 
We then evaluated the dose-response of stimulation at concentrations 
lower than 200µM of H2O2 on the expression of OLs differentiaton markers. 
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The cells were differentiated with 100nM PMA in medium without serum for 
4 days and treated for 30 minutes with H2O2. 
Figure 17 shows that H2O2 reduces of -SMA. On the contrary, 
differentiation of the cells is accompanied by an increase of P-CREB levels. 
Furthermore, H2O2 200µM dose seems a very effective inducer of 
differentiation. Therefore, we used this dose of H2O2 for our experiments. 
 
 
 
 
 
Figure 17. Short-term effects of H2O2 on -SMA and P-CREB levels in M03-13 cells. 
Cells were differentiated with 100nM PMA in medium without serum for 4 days, treated 
for 30min with 10, 50 or 200µM H2O2 and then -SMA and P-CREB levels were evaluated 
by Western blotting analysis. The histogram shows the values (means  SEM) relative to 
controls obtained by densitometric analysis of protein bands normalized to -Tubulin in 
three independent experiments. 
 
 
 
We also quantified the levels of MBP in M03-13 cells treated for 4 days 
with H2O2 200 µM; flow cytometric analysis shown an increase of total MBP 
protein levels (Figure 18). 
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Figure 18. Effects of H2O2 on MBP levels in M03-13 cells (4d). 
Increase of MBP protein levels in M03-13 cells treated for 4 days with 200µM H2O2. 
Immunoreactivity for MBP was evidenced by indirect immunofluorescence and flow 
cytometric analysis, using primary antibodies against MBP and CY3-conjugated anti rabbit 
IgG as secondary antibodies. Control was treated with secondary antibodies alone. 10,000 
cells were counted for each sample. 
N.D. indicates Not Differentiated cells, growing in complete medium. A sample of cells 
differentiated for 4 days with 100nM PMA in medium without serum is also shown (Diff.). 
The histogram shows the mean  SEM in three independent experiments. *p<0.01 vs N.D. 
 
 
 
 
 
On the contrary, differentiation of cells for 4 days with H2O2 was 
accompanied by a significant decrease of cytosolic MBP levels, measured by 
protein fractionation and Western blotting analysis. These apparently 
contradictory data can be explained by the fact that MBP translocates from 
cytosol to the detergent-resistant lipid rafts membrane microdomain following 
differentiation (Figure 19). 
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Figure 19. Effects of H2O2 on cytosolic MBP levels in M03-13 cells (4d). 
Western blotting analysis of cytosolic MBP levels in M03-13 cells treated for 4 days with 
200µM H2O2. 
N.D. indicates Not Differentiated cells, growing in complete medium. A sample of cells 
differentiated for 4 days with 100nM PMA in medium without serum is also shown (Diff.). 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of MBP normalized to -Tubulin in three independent experiments. 
*p< 0.01 vs N.D. 
 
 
 
 
The effects of the PMA stimulus (100 nM) in serum-free medium or of 
H2O2 (200 μM) for 1 and 4 days on -SMA and MBP levels were also 
evaluated by confocal microscopy analysis. 
Figure 20 shows that the signal derived from antibodies directed against 
α-SMA decreases both in cells stimulated by PMA and with H2O2, compared 
to undifferentiated cells (Table 1). 
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Figure 20. Decrease of α-SMA levels in M03-13 cells after treatment with PMA or 
H2O2 (1d-4d). 
α-SMA staining after 1 or 4 days of differentiation of M03-13 cells with 100nM PMA in 
medium without serum or with 200µM H2O2. Cells were stained with anti human α-SMA 
antibodies and CY2-conjugated anti mouse IgG as secondary antibodies and analyzed by 
confocal microscopy. 
Ctr was treated with secondary antibodies and nuclear dye DAPI alone. N.D. indicates Not 
Differentiated cells, growing in complete medium. 
 
 
N.D. PMA 1d PMA 4d H2O2 1d H2O2 4d 
104.83±8.5 57.28±14.4 43.27±7 51.12±8.3 38.01±7.4 
 
Table 1. Quantitative analysis of the Figure 20. 
The values are means ± SD of 25 cells for each sample. 
 
 
Besides, in M03-13 cells immunostained with antibodies directed 
against MBP, the signal increased in differentiated cells with PMA, compared 
with undifferentiated cells and accumulated in cellular processes; a similar 
increase of the fluorescent signal was observed in the cells treated with H2O2 
(Figure 21 and Table 2). 
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Figure 21. Increase of MBP levels in M03-13 cells after treatment with PMA or H2O2 
(1d-4d). 
MBP staining after 1 or 4 days of differentiation of M03-13 cells with 100nM PMA in 
medium without serum or with 200µM H2O2. Cells were stained with anti human MBP 
antibodies and CY3-conjugated anti rabbit IgG as secondary antibodies and analyzed by 
confocal microscopy. 
Ctr was treated with secondary antibodies and nuclear dye DAPI alone. N.D. indicates Not 
Differentiated cells, growing in complete medium. 
 
N.D. PMA 1d PMA 4d H2O2 1d H2O2 4d 
39.86±4.6 71.73±21.4 97.93±38.4 56.44±3.9 63.91±4.8 
 
Table 2. Quantitative analysis of the Figure 21. 
The values are means ± SD of 25 cells for each sample. 
 
Moreover, we measured, by confocal fluorescence analysis, the effects 
of the same stimuli on the expression levels of Olig-2, a specific OLs 
differentiation marker, in PMA-differentiated cells, as well as in H2O2-
stimulated cells. The signal progressively increased compared to 
undifferentiated growing cells (Figure 22 and Table 3). In the figure the DAPI 
(nuclei) and Olig-2 signals are split in different panels to better appreciate the 
nuclear staining of Olig-2. 
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N.D. PMA 1d PMA 4d H2O2 1d H2O2 4d 
39.86±4.6 50.61±6.4 72.27±9.4 54.2±9.9 54.99±2.8 
 
Table 3. Quantitative analysis of the Figure 22. 
The values are means ± SD of 25 cells for each sample. 
 
 
Afterwards, we found that chronic stimulation (4 days) of the cells with 
H2O2 (200 µM) induced P-ERK1/2, P-CREB, Olig-2 and decreased -SMA 
levels similarly to PMA (100 nM) (Figure 23). Also, the same markers were 
evaluated in response to H2O2 in cells preincubated with N-acetyl-L-cysteine 
(NAC, 50 µM), a precursor of Glutathione, a natural antioxidant that protects 
cells, together with catalase and SOD, from ROS toxicity: H2O2 effects were 
reversed by treatment with NAC (data not shown). 
 
 
 
Figure 23: Effects of H2O2 on differentiation markers in M03-13 cells (4d). 
Western blotting analysis of -SMA, P-ERK1/2, P-CREB and Olig-2 levels in M03-13 
cells treated for 4 days with 200µM H2O2. 
N.D. indicates Not Differentiated cells, growing in complete medium. A sample of cells 
differentiated for 4 days with 100nM PMA in medium without serum is also shown. 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of MBP normalized to -Tubulin in three independent experiments. 
*p< 0.01 vs N.D. 
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Real-time PCR analysis evidenced a reduction of α-SMA mRNA levels 
in M03-13 cells treated for 4 days with H2O2 relative to control cells (Figure 
24), confirming the decrease of α-SMA protein levels evidenced by Western 
blotting experiments. 
 
 
 
Figure 24: -SMA m-RNA levels in M03-13 cells treated with PMA or H2O2 (4d). 
RT-PCR analysis of -SMA m-RNA levels in M03-13 cells treated for 4 days with 100nM 
PMA in medium without serum or with 200µM H2O2. N.D. indicates Not Differentiated 
cells, growing in complete medium. 
Expression values were normalized using glucose-6-phosphate-dehydrogenase mRNA 
(G6PD). The histogram shows means  SEM values relative to control in three 
independent experiments. 
 
 
4.2.1. Study of pathways involved in oxidative stress and oligodendrocytes 
         differentiation 
To identify the signalling pathways involved in H2O2 and PMA-
induced OLs differentiation, we used specific inhibitors of signaling 
molecules involved in oxidative stress and/or OLs differentiation. 
We first evaluated the involvement of NADPH-ox-dependent ROS 
production in PMA-mediated differentiation using Apocynin, a specific 
NAPDH oxidase inhibitor. 
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To this aim the effects of stimulation with PMA (100 nM) in serum-
free medium or with H2O2 (200 μM) for 4 days, were evaluated, on the 
expression levels of P-ERK1/2, P-CREB, Olig-2 and Ha-Ras, with or without 
Apocynin (50 µM), by Western-blotting. Incubation of cells with H2O2 and 
apocynin for 4 days, induced cell death. 
Figure 25 shows an increase in protein levels seen following the 
stimulation with PMA or with H2O2; the effect of PMA is reversed by 
preincubation with Apocynin. 
 
 
 
 
Figure 25. Apocynin reverts PMA effect (4d). 
Western blotting analysis of p-ERK1/2, p-CREB, Olig-2 and Ha-Ras expression levels in 
M03-13 cells stimulated with H2O2 (200 μM) or PMA (100 nM) for 4 days in serum-free 
medium in the presence or absence of Apocynin (50 µM). N.D. indicates Not 
Differentiated cells, growing in complete medium. 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of protein bands normalized to total-ERK1/2, compared to 
undifferentiated control, in three independent experiments. * p< 0.01 vs N.D. 
 
 
 
The same protocol was used to verify the action of 
Bisindolylmaleimide (BIM, 100 µM), a PKC inhibitor, on differentiation 
induced by H2O2 or by PMA; increased expression levels, verified by 
Western-blot, of proteins p-ERK1/2, p-CREB, Olig-2 and Ha-Ras, as a result 
of stimulation with PMA or H2O2, were reversed by the BIM (Figure 26). 
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Similarly MBP, using confocal microscopy, decreased in the samples 
treated with BIM and PMA (100 nM) or with H2O2 (200 μM) for 4 days 
compared with that cells stimulated with PMA or H2O2 alone (Figure 27 and 
Table 4). 
 
 
 
Figure 26. BIM reverts PMA and H2O2 effects (4d). 
Western blotting analysis of p-ERK1/2, p-CREB, Olig-2 and Ha-Ras expression levels in 
M03-13 cells stimulated with H2O2 (200 μM) or PMA (100 nM) for 4 days in serum-free 
medium in the presence or absence of BIM (100 µM). N.D. indicates Not Differentiated 
cells, growing in complete medium. 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of protein bands normalized to total-ERK1/2 compared to 
undifferentiated control, in three independent experiments. * p< 0.01 vs N.D. 
 
 
 68 
 
Figure 27. BIM reverts PMA and H2O2 effects (4d) on MBP levels in M03-13 cells. 
MBP staining after 1 or 4 days of differentiation of M03-13 cells with 100nM PMA in 
medium without serum or with 200µM H2O2 in the presence or absence of BIM (100 µM). 
Cells were stained with anti human MBP antibodies and CY3-conjugated anti rabbit IgG as 
secondary antibodies and analyzed by confocal microscopy. 
Ctr was treated with secondary antibodies and nuclear dye DAPI alone. N.D. indicates Not 
Differentiated cells, growing in complete medium. 
 
N.D. PMA 1d PMA 4d BIM+PMA 4d 
37.49±2.9 50.71±7.9 96.53±11.6 38.10±11.4 
BIM 4d H2O2 1d H2O2 4d BIM+ H2O2 4d 
44.84±9.5 45.85±6.2 51.54±2.7 35.51±4.1 
 
Table 4. Quantitative analysis of the Figure 27. 
The values are means ± SD of 25 cells for each sample. 
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The expression levels of -SMA, P-ERK1/2, P-CREB were also 
measured after 4 days of differentiation with PMA (100 nM) in the absence of 
serum or with H2O2 in the presence or absence of MEK-ERK1/2 pathway 
inhibitor, PD98059 (PD, 40 µM). Incubation of cells with H2O2 and PD, for 4 
days, induced cell death. As shown in Figure 28, P-ERK1/2 and P-CREB 
were induced by differentiation; in contrast, levels of -SMA were reduced by 
differentiation. PD reversed the effect of PMA on the expression levels of 
these proteins. 
 
 
Figure 28. PD reverts PMA effect (4d). 
Western blotting analysis of α-SMA, p-ERK1/2 and p-CREB expression levels in M03-13 
cells stimulated with H2O2 (200 μM) or PMA (100 nM) for 4 days in serum-free medium 
in the presence or absence of PD (40 µM). N.D. indicates Not Differentiated cells, growing 
in complete medium. 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of protein bands normalized to total-ERK1/2 compared to 
undifferentiated control, in three independent experiments. *p<0.01 vs N.D. 
 
 
 
4.3. Stimulation of cells with biological samples 
Immunocytochemistry and immunohistochemistry previous studies 
have shown that in chronic demyelinating lesions of MS patients is present a 
small number of pro-OL and an increased number of OPCs, suggesting an 
impairment in the OPCs maturation (66, 67). To assess the presence in 
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biological fluids (serum and CSF) of MS patients factors (such as Ig extracted 
from serum or CSF) that alter the redox state and differentiation of OPCs, we 
evaluated the effects of stimulation with these biological samples, in 
differentiated OLs, on expression levels of proteins involved in 
differentiation. 
 
 
4.3.1. Effect of CSF from MS patients on the molecular mechanism of 
          differentiation in oligodendrocytes 
To evaluate whether in CSF from MS patients there are molecules that 
alter the OLs differentiation, we incubated M03-13 cells, grown in FBS-free 
DMEM supplemented with 100nM of PMA for 1or 4 days (pro-differentiation 
conditions), in the presence of CSF (30% v/v) of MS or control patients. 
In these conditions -SMA, measured by confocal microscopy, which 
decreased as a result of differentiation for 4 days, in presence of CSF of MS 
patients displayed expression levels comparable to that of undifferentiated 
cells; this did not occur after treatment with CSF of control patients (Figure 
29 and Table 5). 
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Figure 29. CSF from MS patients inhibits PMA differentiative effect on α-SMA levels 
(4d). 
The cells were stained with anti-α-SMA and anti-mouse secondary antibody conjugated to 
CY2 and the nuclear dye DAPI, and analyzed by confocal microscopy. 
N.D. indicates Not Differentiated cells, growing in complete medium; Diff was treated 
only with PMA (100 nM) for 4 days in serum-free medium; CSF N indicates cells 
stimulated by CSF from control patients; CSF MS indicates cells stimulated with CSF of 
MS patients. 
 
 
N.D. Diff. CSF N1 CSF N2 CSF MS1 CSF MS2 
98.21±4.1 38.15±2.1 36.18±1.7 58.16±6.3 123.02±30.7 101.38±8.7 
 
Table 5. Quantitative analysis of the Figure 29. 
The values are means ± SD of 25 cells for each sample. 
 
Under the same conditions MBP, measured by confocal microscopy, 
which increased as a result of differentiation for 1 day, in the presence of CSF 
of MS patients displayed expression levels comparable to that of 
undifferentiated cells; this did not occur after treatment with CSF of control 
patients (Figure 30 and Table 6). 
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Figure 30. CSF from MS patients inhibits PMA differentiative effect on MBP levels 
(1d). 
The cells were stained with anti-MBP and anti-rabbit secondary antibody conjugated to 
CY3 and the nuclear dye DAPI, and analyzed by confocal microscopy. 
N.D. indicates Not Differentiated cells, growing in complete medium; Diff was treated 
only with PMA (100 nM) for 1 day in serum-free medium; CSF N indicates cells 
stimulated by CSF from control patients; CSF MS indicates cells stimulated with CSF of 
MS patients.. 
 
N.D. Diff. CSF N1 CSF N2 CSF MS1 CSF MS2 
96.87±4.2 127.15±8.6 100.44±5.5 121.79±12 89.26±5 86.66±4.6 
 
Table 6. Quantitative analysis of the Figure 30. 
The values are means ± SD of 25 cells for each sample. 
 
Using the same protocol, we evaluated the effects of stimulation with 
CSF on the transcriptional factor Olig-2. In M03-13 cells, after 1 day of 
stimulation with PMA (100 nM) in the absence of serum, the specific Olig-2 
signal increased compared to growing cells (N.D.), and became evident in the 
cytosol, in cells treated for 1 day with PMA in the presence of CSF of MS 
patients, the signal derived from Olig-2 was similar to that of undifferentiated 
cells (Figure 31 and Table 7). 
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N.D. Diff. CSF N1 CSF N2 CSF MS1 CSF MS2 
95.21±7.6 114.56±5.1 93.35±5.4 103.12±3.4 84.77±8.5 93.57±2.6 
 
Table 7. Quantitative analysis of the Figure 31. 
The values are means ± SD of 25 cells for each sample. 
 
4.3.2. Effect of IgG from MS patients on oligodendrocytes differentiation 
Further experiments for the analysis of the effects of biological samples 
on cellular maturation processes of OLs, were performed by incubating M03-
13 cells for 1 day with PMA (100 nM), in the absence of serum (pro-
differentiative conditions), and in the presence of IgG (200 µg/ ml), purified 
by affinity chromatography, from the serum of MS and control patients. 
In this case the expression levels of P-ERK1/2 and Olig-2 were 
assessed by Western-blot. Both differentiation markers increased as a result of 
differentiation; in cells incubated in the presence of IgG purified from serum 
of patients with MS, their levels were lower than that observed after treatment 
of cells with IgG from control patients (Figure 32). 
 
Figure 32. IgG from MS patients inhibit PMA differentiative effect on p-ERK1/2 and 
Olig-2 expression levels (1d). 
Western blotting analysis of p-ERK1/2 and Olig-2 expression levels in M03-13 cells 
stimulated with PMA (100 nM) for 1 day in serum-free medium in the presence of IgG 
(200 µg/ml) purified from the serum of patients with and not from MS. N.D. indicates Not 
Differentiated cells, growing in complete medium; Diff. was treated only with PMA (100 
nM) for 1 day in serum-free medium; Ig N indicates cells stimulated by IgG of control 
patients; Ig MS indicates cells stimulated with IgG of patients with MS. 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of protein bands normalized to α-Tubulin, compared to cells 
stimulated by IgG control patients, in three independent experiments. *p<0.01 vs Ig Ctr. 
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Using the same protocol and confocal microscopy, we monitored the 
effects on -SMA after 4 days, and on MBP and on Olig-2 after 1 day. 
In M03-13 cells incubated with anti--SMA antibodies, after 4 days of 
stimulation with PMA (100 nM) in the absence of serum, the signal decreased 
compared to growing cells (N.D.); in cells treated for 4 days with PMA, in the 
presence of IgG from MS patients, the signal arising from -SMA was 
increased (Figure 33 and Table 8). 
 
 
Figure 33. IgG from MS patients inhibit PMA differentiative effect on α-SMA levels 
(4d). 
The cells were stained with anti-α-SMA and anti-mouse secondary antibody conjugated to 
CY2 and the nuclear dye DAPI, and analyzed by confocal microscopy. 
N.D. indicates Not Differentiated cells, growing in complete medium; Diff. was treated 
only with PMA (100 nM) for 4 days in serum-free medium; Ig N indicates cells stimulated 
by IgG of control patients; Ig MS indicates cells stimulated with IgG of MS patients. 
 
 
 
N.D. Diff. Ig N1 Ig N2 Ig MS1 Ig MS2 
125.02±11.1 36.15±4.8 40.17±1.8 37.44±3.5 69.74±12.9 81.85±4.4 
 
Table 8. Quantitative analysis of the Figure 33. 
The values are means ± SD of 25 cells for each sample. 
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In M03-13 cells incubated with anti-MBP antibodies, after 1 day of 
stimulation with PMA (100 nM) in the absence of serum, the signal increased 
compared to growing cells (N.D.); in cells treated for 1 day with PMA, in the 
presence of IgG from MS patients, the signal arising from MBP was 
decreased (Figure 34 and Table 9). 
 
 
Figure 34. IgG from MS patients inhibit PMA differentiative effect on MBP levels 
(1d). 
The cells were stained with anti-MBP and anti-rabbit secondary antibody conjugated to 
CY3 and the nuclear dye DAPI, and analyzed by confocal microscopy. 
N.D. indicates Not Differentiated cells, growing in complete medium; Diff. was treated 
only with PMA (100 nM) for 1 day in serum-free medium; Ig N indicates cells stimulated 
by IgG of control patients; Ig MS indicates cells stimulated with IgG of MS patients. 
 
 
 
N.D. Diff. Ig N1 Ig N2 Ig MS1 Ig MS2 
97.1±3.5 150.55±4.4 112.20±13.9 144.18±12.3 88.84±4.1 86.39±5.9 
 
Table 9. Quantitative analysis of the Figure 34. 
The values are means ± SD of 25 cells for each sample. 
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Similar results were obtained in M03-13 cells incubated with anti-Olig-
2 antibodies, after 1 day of stimulation with PMA (100 nM) in the absence of 
serum: the signal increased compared to growing cells (N.D.), and was 
evident in the cytosol; in cells treated for 1 day with PMA in the presence of 
IgG from MS patients, the signal derived from Olig-2 was decreased (Figure 
35 and Table 10). 
 78 
 
F
ig
u
re
 3
5
. 
Ig
G
 f
ro
m
 M
S
 p
a
ti
en
ts
 i
n
h
ib
it
 P
M
A
 d
if
fe
re
n
ti
a
ti
v
e 
ef
fe
ct
 o
n
 O
li
g
-2
 l
ev
el
s 
(1
d
).
 
T
h
e 
ce
ll
s 
w
er
e 
st
ai
n
ed
 w
it
h
 a
n
ti
-O
li
g
-2
 a
n
d
 a
n
ti
-r
ab
b
it
 s
ec
o
n
d
ar
y
 a
n
ti
b
o
d
y
 c
o
n
ju
g
at
ed
 t
o
 C
Y
3
 a
n
d
 t
h
e 
n
u
cl
ea
r 
d
y
e 
D
A
P
I,
 a
n
d
 a
n
al
y
ze
d
 b
y
 
co
n
fo
ca
l 
m
ic
ro
sc
o
p
y
. 
F
o
r 
ea
ch
 i
m
ag
e 
ar
e 
sh
o
w
n
 t
h
re
e 
p
an
el
s:
 o
n
 t
h
e 
le
ft
 O
li
g
-2
 (
re
d
);
 o
n
 t
h
e 
ce
n
te
r 
n
u
cl
ei
 (
b
lu
e)
; 
o
n
 t
h
e 
ri
g
h
t 
th
e 
m
er
g
ed
 i
m
ag
e.
 
N
.D
. 
in
d
ic
at
es
 N
o
t 
D
if
fe
re
n
ti
at
ed
 c
el
ls
, 
g
ro
w
in
g
 i
n
 c
o
m
p
le
te
 m
ed
iu
m
; 
D
if
f.
 w
as
 t
re
at
ed
 o
n
ly
 w
it
h
 P
M
A
 (
1
0
0
 n
M
) 
fo
r 
1
 d
ay
 i
n
 s
er
u
m
-f
re
e 
m
ed
iu
m
; 
Ig
 N
 i
n
d
ic
at
es
 c
el
ls
 s
ti
m
u
la
te
d
 b
y
 I
g
G
 o
f 
co
n
tr
o
l 
p
at
ie
n
ts
; 
Ig
 M
S
 i
n
d
ic
at
es
 c
el
ls
 s
ti
m
u
la
te
d
 w
it
h
 I
g
G
 o
f 
M
S
 p
at
ie
n
ts
. 
 79 
N.D. Diff. Ig N1 Ig N2 Ig MS1 Ig MS2 
88.88±1.1 124.58±4.5 136.03±9.5 128.8±4.1 102.48±7.4 84.15±5.7 
 
Table 10. Quantitative analysis of the Figure 35. 
The values are means ± SD of 25 cells for each sample. 
 
Finally, to assay the tissue-specificity of the IgG effect on the 
expression levels of P-ERK1/2, we applied the same protocol on another cell 
line, the HEK293. Also in these cells, PMA (100 nM) treatment for 1 day, 
stimulated P-ERK1/2, but this effect was not modified by the presence of IgG 
from MS patients (Figure 36). 
 
Figure 36. Inhibition of PMA differentiative effect by Ig from MS patients is tissue 
specific. 
Western blotting analysis of p-ERK1/2 expression levels in M03-13 and HEK293 cells 
stimulated with PMA (100 nM) for 1 day in serum-free medium in the presence of IgG 
(200 µg/ml) purified from the serum of patients with and not from MS. N.D. indicates Not 
Differentiated cells, growing in complete medium; Diff. was treated only with PMA (100 
nM) for 1 day in serum-free medium; Ig N indicates cells stimulated by IgG of control 
patients; Ig MS indicates cells stimulated with IgG of MS patients. 
The histogram shows the values (means  SEM) relative to control obtained by 
densitometric analysis of protein bands normalized to α-Tubulin, compared to cells 
stimulated by IgG control patients, in three independent experiments. *p<0.01 vs Ig Ctr. 
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CHAPTER V 
DISCUSSION AND CONCLUSIONS 
 
OLs, the myelin-forming cells of the CNS, are derived from bipotential 
precursor cells. In culture, these cells differentiate to astrocytes type II in the 
presence of serum, and proliferate or differentiate to mature OLs when certain 
growth factors are added (81). These cells respond to serum deprivation by a 
cessation of cell proliferation and by an increase in morphological 
differentiation (138). 
In this study, M03-13 cells, a cell line with oligodendroglial properties, 
were used to search for a link between oxidative stress and differentiation. 
We identified several molecular markers modulated by differentiation 
stimuli such as PMA (PKC activator). We identified the effective 
concentrations of these substances and the incubation time required for the 
modulation of markers of differentiation, following the pattern of their 
expression over time up to 4 days of treatment. 
We demonstrated a close link between ROS and differentiative 
processes of OLs. The chronic stimulation of the cells with low doses of H2O2 
induces the differentiation of OPC in differentiated cells; H2O2 modulates, in 
fact, different markers of differentiation, in similar manner to chronic 
treatment with PMA 100nM in medium without serum. 
Several studies have shown that H2O2 activates signaling pathways 
associated with protein tyrosine kinases and their downstream signaling 
components, such as MAPKs and transcription factors regulating cell survival 
(141); our results show that P-ERK1/2 and P-CREB, in fact, increase with 
differentiation. 
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MBP, protein associated with the process of myelinating OLs, and 
Olig-2, a specific OLs transcription factor, increase with differentiation and 
chronic stimulation of the cells with low doses of H2O2 exert similar effects. 
Instead -SMA, a negative marker of differentiation, decreases with 
differentiation induced both by PMA and H2O2. 
Important experimental evidence suggest the existence of a significant 
contribution of ROS in the formation and persistence of chronic 
demyelinating lesions in MS. This condition of oxidative stress is associated 
with epigenetic modulation of gene transcription and with a block of OLs 
maturation. 
Therefore, we demonstrated that the differentiation of OLs can be 
monitored and manipulated in culture under very defined conditions. 
Moreover, we discovered that hydrogen peroxide at low dose stimulates 
differentiation, whereas at higher doses induces oxidative stress and 
compromises cell viability. 
To study the signal transduction pathway involved in PMA and H2O2–
induced OLs differentiation we treated the cells with differentiation stimuli in 
the presence of different inhibitors: 
 Apocynin’s observed anti-inflammatory capabilities proved to be 
a result of its ability to selectively prevent the formation of free 
radicals, oxygen ions, and peroxides in the body. 
MODE OF ACTION: NADPH oxidase is an enzyme that effectively 
reduces O2 to superoxide (O2
–•
), which can be used by the 
immune system to kill bacteria and fungi. Apocynin is a selective 
inhibitor of NADPH oxidase activity and thus is effective in 
preventing the production of the superoxide in human white 
blood cells or neutrophilic granulocytes (142). 
Apocynin was used to determine whether ionic activation due to 
proton flux across the membrane of renal medulla cells was 
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coupled to NADPH oxidase production of superoxide. Apocynin 
was introduced to the cells and completely blocked the 
production of superoxide, and was a key component in 
determining that the proton outflow was responsible for the 
activation of NADPH oxidase (143). 
 Bisindolylmaleimide (BIM) is a selective inhibitor of PKC, that 
enhances Fas- and TRAIL-mediated apoptosis and inhibits T 
cell-mediated autoimmune diseases. 
 PD 98059 is a selective, reversible, and cell-permeable inhibitor 
of MEK, that acts by inhibiting the activation of MAP kinase and 
subsequent phosphorylation of MAP kinase substrates. 
We observed that these three inhibitors reverse PMA effects, and BIM 
reverts H2O2 effects too; we don’t yet know if Apocynin and PD reverse H2O2 
effects, because used doses caused cell death. 
On the basis of these results, we have hypothesized that stimuli of PMA 
and H2O2 may converge into one pathway: a seven transmembrane receptor 
activates phospholipase C (PLC); inositol triphosphate leads to an increase 
(IP3), which, by interacting with its receptor (IP3-R) in the endoplasmic 
reticulum (ER), causes an increase of intracellular Ca
2+
 concentration, which, 
together with diacylglycerol, activates PKC; PKC acts on the NADPH-
oxidase, resulting in an increase of ROS, which activate the MAP kinase 
cascade, that self-amplifies the circuit (Figure 37). 
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Figure 37. Scheme of PKC/ROS signaling pathways involved in OLS differentiation. 
ROS are downstream of PMA and are generated by NADPH oxidase to induce 
differentiation of OLs precursors. 
 
 
An important objective of the project is to verify the presence in 
biological fluids from MS patients of factors able to induce oxidative stress 
and/or to alter OLs differentiation. The CSF is in communication with the 
brain interstitial fluid and therefore substances or antibodies present in CSF 
can reach neurons and glial cells activating specific cellular responses. 
Moreover, in MS patients, it has been demonstrated a disruption of the BBB; 
therefore, it is possible to hypothesize that serum antibodies can reach the 
CNS, producing demyelination. Based on these assumptions, the effects of 
liquor and Ig from serum and liquor from MS patients were analyzed on the 
OLs differentiation through the analysis of the expression levels of 
differentiation markers. 
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We found that in the CSF from patients with MS there is a molecule(s) 
that blocks the OLs differentiation; this inhibition may alter the normal 
remyelination process, giving rise to permanent neurological damage. 
Using the CSF or IgG from serum of MS patients to stimulate the cells, 
we found that P-ERK1/2, MBP and Olig-2 expression levels are significantly 
reduced compared with control group, likewise to undifferentiated cells. 
Instead, -SMA expression levels are decreased in cells stimulated by CSF or 
IgG from serum of MS patients, similarly to undifferentiated cells. Therefore, 
in biological fluids from MS patients, there are molecules that act on redox 
pathways and inhibits the OLs differentiation. Importantly, this effect is cell 
specific, since it is detectable only in OLs and the source of inhibition is in the 
serum, presumably an Ig. This opens a new scenario in the search of the 
pathogenic clue of MS. 
Previous studies have shown that in chronic demyelinating lesions in 
MS patients there is a small number of pro-OL and an increased number of 
OPCs, suggesting an impairment in the OPCs differentiation (66, 67). 
This data is actually based on immunocytochemistry and 
immunohistochemistry investigations of the brain tissue, while our results 
allow us to evaluate the differentiation mechanisms at a cellular level and not 
organ level. 
 
5.1. Future perspectives 
In the next future we wish to validate the effects of Ig derived from 
CSF on OLs precursors and differentiated cells and the effects of CSF and Ig 
derived from serum and CSF on OLs differentiated with H2O2. 
Finally, the identification of specific markers of oxidative stress and/or 
cell differentiation, modulated in M03-13 cells exposed to biological fluids 
from MS patients, is relevant because it can represent an indirect 
measurement of a specific cell receptor activation, giving the opportunity to 
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use thisassay as guide identify the receptor affected. The identification of a 
putative receptor target of molecules present in the biological fluids of MS 
patients will pave the way to dissect the primary cause of the disease. The 
identification of receptor will be performed through the use of specific 
inhibitors. Once identified , the receptor will be purified by chromatography 
and an in vitro binding assay the blood serum Ig from patients will be 
developed (131). 
It is not yet clear whether the axonal damage, the main cause of 
disability in MS, is secondary to the myelin sheath damage. Therefore, we 
cannot exclude that neurons represent the direct target of auto-antibodies or 
substances present in body fluids of MS patients leading to deficiency of 
axon-glial signaling and demyelination. Consequently, primary cultures of 
mouse neurons will also be used in our study. 
From these experiments we expect to get information on the nature and 
identity of factors that can affect the maturation processes of OLs and on the 
pathogenesis of the disease. 
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APPENDIX 
ABBREVIATIONS USED 
 
 
 
 
 
 
 
 
 
 
 
 
 Apo, Apocynin 
 BIM, Bisindolylmaleimide 
 CSF, Cerebrospinal fluid 
 CREB protein, Cyclic AMP 
Response Element Binding 
Protein 
 ERK ½, Extracellular Signal-
Regulated Kinases 1/2 
 H-Ras, Harvey-Ras 
 MAPK, Mitogen-Activated 
Protein Kinase 
 MS, Multiple sclerosis 
 MBP, Myelin Basic Protein 
 NAC, N-acetyl-L-cysteine 
 NADPH oxidase, 
Nicotinamide Adenine 
dinucleotide phosphate-
oxidase 
 OLs, Oligodendrocytes 
 OPCs, Oligodendrocyte 
precursor cells 
 Olig-2, Oligodendrocyte 
Transcription Factor 2 
 PD, PD98059 (2′-Amino-3′-
methoxyflavone) 
 PMA, Phorbol-12-Myristate-
13-Acetate 
 PI3K, Phosphatidylinositol 3-
kinase 
 PLC, Phospholipase C 
 PDGF, Platelet-derived growth 
factor 
 PI, Propidium Iodide 
 PKC, Protein kinase C 
 ROS, Reactive Oxygen 
Species 
 α-SMA, α-Smooth Muscle 
Actin, 
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